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Mycobacterium tuberculosis still remains a major cause of tuberculosis(TB) and death. In 
addition, nontuberculous mycobacteria (NTM) play a significant role in the aetiology of 
tuberculosis-like syndromes. A diagnosis of M. tuberculosis as the causative agent of 
pulmonary TB using only clinical symptoms may be inadequate and inaccurate in some cases 
since M.bovis, M.avium, M.kansasii, and M.intracellulare may all produce a pulmonary 
disease in humans that may be indistinguishable from that caused by M.tuberculosis. 
 
For diagnostic purposes, current mycobacterial identification strategies to the species level 
primarily rely on phenotypic analysis, complex biochemical tests, cultivation on specific 
growth media and genotype analysis. However, the main disadvantages that are associated 
with these techniques include extensive processing times (6-12 weeks to confirm a positive 
identification) and misidentification. Both factors severely hinder the control and 
management of diseases associated with mycobacteria, particularly tuberculosis. Apart from 
an increased patient mortality, interpersonal transmission of mycobacterial infections may 
increase. This scenario will also result in the prescription of inappropriate anti-tubercular 
treatment regimes.  
 
The present study assesses the feasibility of using MALDI-TOF MS proteomic profiling as a 
rapid and precise technology to identify mycobacteria in Kwazulu-Natal, South Africa which 
is currently a global epicentre of mycobacterial-associated diseases. In this study a modified 
EFA protein extraction protocol that incorporates an initial cell envelope delipidation step was 
formulated and shown to produce mass spectra that were unique and highly reproducible. The 
spectra were used to create an independent main spectral profile reference library (CMEFA-
MSP) representing clinically relevant American Type Culture Collection (ATCC) 
mycobacterial strains. Interestingly, this proof of concept study clearly demonstrates that 
MALDI-TOF MS-based biotyping of mycobacteria using the CMEFA-MSP reference library 
correctly identified 11 blind-coded ATCC strains sourced from an autonomous facility to the 
genus and species level with 100% accuracy.In addition the CMEFA-MSP reference library 
was employed to differentiate 39 blind-coded clinical mycobacterial isolates. Importantly all 
CMEFA-derived samples of the 39 clinical mycobacterial isolates displayed log score values 
of ≥ 2.3 and were correctly identified to the species level. This strongly suggests that MALDI-
TOF MS when used in conjunction with the CMEFA sample preparation protocol has 
potential as a simple and cost-effective alternative for the unambiguous identification of 
clinically important mycobacteria. Moreover, individual members of the MTBC and NTM 
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Tuberculosis is an ancient infection and is responsible for a major percentage of the mortality 
and morbidity of HIV/AIDS, and poses a major threat to families and communities [1,2]. The 
causative agent of this airborne disease is Mycobacterium tuberculosis (MTB) and historically 
has been responsible for more deaths than any other single disease entity. According to the 
World Health Organisation (WHO), 8.8 million new cases and 1.7 million deaths from 
tuberculosis occur each year [3-5]. Approximately one third of the world population is 
latently infected with MTB carrying a 10% lifetime risk of developing the disease[6,7]. 
Although the prevalence of tuberculosis has declined in industrialized countries, 85% of 
tuberculosis cases occur in developing countries particularly in 22 high burden countries[8-
10]. Sub-Saharan Africa, Eastern Europe and Asia have a high burden of pulmonary 
tuberculosis and have reported an ever-increasing resistance to antituberculous drugs.  
 
Seventy two countries have reported on the prevalence of multidrug-resistant tuberculosis, a 
form of tuberculosis resistant to both isoniazid and rifampicin[11,12]. A more deadly form of 
drug-resistant tuberculosis known as extensively drug resistant tuberculosis (XDR-TB) has 
emerged and is defined as MDR-TB that is resistant to at least one of the fluoroquinolones 
(ofloxacin) plus an aminoglycoside/cyclic peptide (kanamycin, capreomycin)[13]. An 
outbreak of XDR-TB occurred in a rural community in KwaZulu-Natal province in South 
Africa and was responsible for almost all deaths in HIV positive individuals in less than one 
month following diagnosis[14]. Of note; KwaZulu-Natal, South Africa has one of the highest 
rates of HIV and active TB cases in the world [12,15,16].  
 
Moreover an increase in the number of infections caused by the nontuberculous mycobacteria 
(NTM) has also been observed in the era of the HIV/AIDS epidemic, with a high level of 
NTM disease occurring in AIDS patients [17-19]. In developed countries nontuberculous 
mycobacteria (NTM) play a significant role in the aetiology of tuberculosis-like syndromes, 
especially in HIV-positive patients[20,21]. Of concern is that a diagnosis of M. tuberculosis 
as the causative agent of pulmonary TB using only clinical symptoms may be inadequate and 
inaccurate in some cases since M.bovis, M.avium, M.kansasii, and M.intracellularemay all 
produce a pulmonary disease in humans that may be indistinguishable from that caused by 
M.tuberculosis[22-24]. 
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Even though the pulmonary disease caused by all Mycobacterial strains are similar, correct 
strain identification is crucial since there is a significant difference in the treatment of NTM 
derived pulmonary infections and tuberculosis caused by M. tuberculosis. Although the 
prevalence of NTM can only be estimated, there is sufficient evidence to show that NTM 
infection rates and actual disease are increasing [6,17,25,26]. Recent reports also show that 
there has been a dramatic increase not only in the total number of NTM mycobacterial species 
but also in the number of clinically significant species[20,27]. 
 
Currently, examination of acid-fast bacilli (AFB) by microscopy allows for the rapid 
diagnosis of tuberculosis. However, one cannot distinguish M. tuberculosis from NTM after 
examination of an AFB smear. It is usually negative in patients with less advanced disease, 
those with HIV co-infection and patients with extra-pulmonary disease[8,10,28]. 
Conventional methods for the identification of NTM in a TB laboratory rely on specific 
phenotypes which include biochemical profiles, pigment production, growth characteristics 
and colony morphology [2,29,30]. Although mycobacterial cultures are important in 
differentiating between M. tuberculosis and NTM, a limitation exists in that culture results 
take up to 6-8 weeks after specimen collection[31]. Furthermore, conventional culture 
methods and biochemical tests are unable to differentiate closely related mycobacterial 
species. It should also be noted that culturing is not widely available in high prevalence 
settings and is only available in reference Tuberculosis laboratories. 
 
A number of rapid molecular assays have been introduced to improve the diagnosis of 
tuberculosis and to provide a presumptive identification prior to culture reports. The 
Genotype MTBDR Plus (Hain-Lifescience, Germany) and the Gene-Xpert (Cepheid, USA) 
are some of the more recent commercially available polymerase chain reaction-based 
approaches introduced for the diagnosis of tuberculosis. These methods cannot be 
implemented in resource poor settings due to high costs and a lack of technical skills[32], and 
routine use of these assays in the primary and secondary level of the health care system are 
thus prevented. 
 
Evolutionary changes of an organism further complicates gene sequencing methods, 
particularly of the 16S rRNA[24,29,33,34]. Sequencing is dependent on existing 
predetermined internet databases for organism identification. In order for gene sequence 
methods to accurately identify mycobacteria, databases need to be specific for high 
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prevalence settings and contain sequences that represent the local population of mycobacteria. 
Recent advances in the field of mass spectrometry have made it possible to use matrix–
assisted laser desorption/ ionization -time-of- flight- mass spectrometry (MALDI-TOF-MS) 
to aid in the identification of mycobacterial species by proteomic profiling[35,36]. MALDI-
TOF MS is an analytical method that is capable of vaporizing and ionizing biological samples 
embedded on a UV-absorbing matrix[35,37]. Differentiation of mycobacterial species by 
MALDI is based on the unique mass spectra obtained from different bacteria due to their 
different protein make-up, which is defined by their unique cell surface biomarkers[38,39]. 
Although this application has not been extensively used for the discrimination of 
mycobacteria, it might be useful for the diagnosis of TB especially in high burden settings. 
 
During the MALDI-TOF MS application process, a matrix containing sample analyte is 
irradiated by the ultraviolet laser of the MALDI-TOF MS instrument. The matrix then 
transfers energy to the sample analyte, allowing for ionization and desorption[39,40]. The 
desorbed ions are accelerated in a flight tube (time of flight) and are analysed according to 
their mass to charge ratio. The ions are first captured and counted by a detector, and  
thereafter they are represented as mass-to-charge signals [41]. Spectral fingerprints 
generatedfrom the mass-to-charge signalsrepresent the molecular composition of a sample 
and facilitate the species and strain level identification of micro-organisms [20].A wide 
variety of prokaryotes have been characterized using this approach, including clinically and 
environmentally relevant Gram positive and negative bacteria. Hetticket al., 2004 [35]have 
shown that mass spectrometry by MALDI is a useful tool in proteomic profiling of various 
mycobacteria including M. tuberculosis. 
 
Currently, there is no consensus on which sample preparation method to use for MALDI-TOF 
MS since cell deposits, cell lysates, or crude bacterial extracts have been previously 
recommended. Given the pathogenic nature of mycobacteria, cellular extraction has been a 
more preferred method option as opposed to whole cell deposits, since this method minimises 
contact with the infectious organism. The current study is aimed at evaluating a newly 
developed chloroform-methanol ethanol-formic acid (CMEFA) cellular extraction protocol 
for the identification and differentiation of clinically significant mycobacterial isolates using 
MALDI-TOF MS. This is one of few studies aimed at establishing the foundation for the 
application of mass spectrometry, particularly MALDI-TOF MS in the field of diagnostic 
mycobacteriology. 
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1.2 AIMS OF THIS STUDY 
i) To optimize a MALDI-TOF MS sample preparation protocol that will enable 
the identification of Mycobacterium species. 
ii) To create a mass spectral database that is representative of typed and locally-
based clinical mycobacterial strains. 
iii) To determine the potential of MALDI-TOF MS analysis to discriminate 
between closely related mycobacteria. 
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IDENTIFICATION OF MYCOBACTERIA 
2.1 INTRODUCTION 
2.1.1 Mycobacterium: The organism 
The genus Mycobacterium consists of an ever-expanding family of approximately 100 
heterogeneous species of rapid and slow growing gram positive acid fast bacilli [1] belonging 
to the members of the Mycobacterium tuberculosis complex (MTBC) and to the 
Nontuberculosis family (NTM). There are five members of the tuberculosis complex and at 
least 80 species of NTM including harmless (non-pathogenic) microbes that live in diverse 
soil and aqueous environments, opportunistic and pathogenic species that infect humans and 
animals[2,3]. The MTBC consists of M.cannetii, M.tuberculosis, M. africanum, M. bovis and 
M.microti[4-6]. Over the past few decades the number of infections caused by mycobacteria 
have increased [1] with M.tuberculosis being the causative agent of tuberculosis disease. 
However, after the onset of human immunodeficiency virus (HIV)pandemic and introduction 
of anti-retroviral and anti-tuberculosis chemoprophylaxis, the incidence of NTM greatly 
increased with Mycobacterium avium complex (MAC) being the most frequent etiologic 
agent followed by M. kansasii, M.gordonae and M.malmoense[5]. A large number NTM of 
blood-stream infections were observed in HIV-AIDS patients with a CD4 count of less than 
200 [7]. 
 
2.1.2 Mycobacteria: Discovery and Classification 
 
The tubercle bacillus was first discovered in 1882 by Robert Koch [7]. Mycobacteria belong 
to the family Mycobacteriaceae and to one of the mycolic-acid genera within the order 
Actinomycelates[7,8]. The genus can be divided into MTBC and NTM mycobacteria (Figure 
2.1). In 1896, Lehman and Neuman coined the term Mycobacterium which makes it the only 
genus of the family Mycobacteriaceae[9]. Previously NTM have been referred to by a variety 
of names, including mycobacteria other than tuberculosis (MOTT), environmental, 
saprophytic, opportunistic and atypical mycobacteria [10]. Since these species were not 
typical of M.tuberculosis, the term atypical mycobacteria was also applied[7,11]. From an 
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international perspective, the term NTM had been widely accepted and endorsed by the 
American Thoracic Society (ATS)[12] and will be used hereon in this review.Timpe and 
Runyon classified NTM according to their rate of growth, colony morphology and 
pigmentation in the presence or absence of light[9]. Types I, II and III (Figure 2.1), the 'slow 
growers'take more than 7 days to cultivateand are further distinguished by colony 
pigmentation[4,5]. NTMs that produce pigments when exposed to light are called 
photochromogens (Type I) [5,7,13].Those that produce pigments when grown in the dark are 
called scotochromogens (Type II) [5].Nonphotochromogens (Type III) are referred to those 
that are not strongly pigmented [5]. NTMs that grow in less than 7 days are termed “rapid 


















Figure 2.1 Classification of Mycobacteria according to Timpe and Runyon[5]. 
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2.1.3 General Characteristics ofMycobacteria 
Mycobacteria are gram positive, aerobic, non-spore forming, non-motile bacteria that may 
appear as either slightly curved or rod shaped bacilli, 0.2-0, 6 x 1.0-10µm in size[4,14]. They 
exhibit acid-alcohol fastness, contain genomic DNA with a molecular GC content of 61-71% 
and display structural similarities of the mycolic acids within their cell walls[9]. These 
organisms also have a number of characteristic features that distinguish them from other 
bacteria. These characteristics play a major role in promoting mycobacteria to produce 
disease and to the pathology of the disease process. In addition they also allow for the control 
and elimination of the infection and to the diagnosis and treatment of disease [11,14].  
 
2.1.4 Cell Wall and Cell Envelope Structures of Mycobacteria 
The cell wall is one of the most important features which differentiate mycobacteria from 
other bacteria[14-16]. The structural organisation of the cell wall is illustrated in Figure 2.2.It 
contains N-glycolylmuramic acid instead of the N-acetylmuramic acid[4,14]. In addition to 
these components, the cell wall is further characterised by high lipid content (60%) 
complexed to a variety of peptides and polysaccharides[4]. The principal component of these 
complexes is a long chain α- branched-β-hydroxy fatty acid called mycolic acid which 
contain up to 90 carbon atoms and are present in all mycobacteria[17]. Unique mycolic acid 
structures such as monocycloproponated and dicycloproponated α-mycolates, and 
methoxymycolates present in M.tuberculosis are also present in some slow growing NTM 
species such as M.gordonae,M.kansasii and M.gastri [11,15].The mycolic acids together with 
two additional layers namely the peptidoglycan (PG) and arabinogalactan (AG) are 
covalently linked together and constitute the cell wall of mycobacterium[14,15]. The lipids 
make the cell surface hydrophobic [14] and as a result will not grow diffusely in liquid media 
unless surface active reagents are present [11]. In the absence of these surface active agents 
the mycobacterial cells adhere tightly to each other and form difficult to disperse clumps of 
cells. 
There is no chemical difference between the cell wall structures of the different 
mycobacterial species [18]. The cross-linked peptidoglycan molecule surrounds the entire 
bacterial cell and is responsible for the size and shape of the cell [19]. Although the 
peptidoglycan structure is common to most eubacteria, two types of structures namely the 
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arabinogalactan and the mycolic acids are covalently linked to the peptidoglycan and are 
unique to mycobacteria (Figure 2.2) [19]. Another striking feature unique to mycobacteria 
derived from ultrastructural studies is that the arabinogalactan has unusual components of 
monosaccharide and linkages and their distal ends are esterified by mycolic acids[17,18]. 
The cell wall together with the plasma membrane constitutes the cell envelope of 
mycobacteria [15] (Figure 2.2). The cell envelope plays an important role by providing 
osmotic protection, transport of ions and nutrients, mechanical support and protection[18]. Of 
relevance, the cell envelope not only provides the elements responsible for the physiology of 
mycobacteria but it also contributes to its disease producing capabilities[15]. It constitutes the 
primary interface between bacteria and the host, providing the first line of defence against the 
damaging assaults of the host immune response [14,18].They are able to modify host cell 
behaviour in favour of the bacteria and resist destructive immune mechanisms [19].The 
envelope with its complex structural components is able to facilitate survival of mycobacteria 
within the host macrophage [11,18]. 
One of the characteristic features is that mycobacteria stain poorly by the Gram staining 
method. The complex composition of the cell wall with high lipid content cannot readily be 
stained by the usual aniline dyes. For this reason they are termed “acid fast bacilli” because 
of their lipid rich cell walls are impermeable to basic dyes unless combined with phenol. 
Once stained, the cells cannot easily be decolorized with acidified organic solvents [4,11]. 
This characteristic has been widely harnessed by the ZiehlNeelsen stain technique as a 
diagnostic tool for the microscopic identification of mycobacteria [3]. 
 
2.1.4.1 Trehalose-6,6,9-dimycolate (TDM) 
In addition to all of the complex lipid structures mentioned, lipids comprising of glycolipids 
(wax D fraction), trehalose containing glycolipids (cord factor), glycopeptidolipids and 
triacylglycerols are loosely bound to the cell wall by hydrophobic forces[20]. These 
components are extractable by organic solvents. Trehalose-6,69-dimycolate (TDM) also 
known as the cord factor is a glycosylated form of mycolic acid present in virulent TB strains 
[19,21].Studies have shown that TDM diffuses into the host cell membranes and damages 
membrane function. Toxic properties from cord factor play a crucial role in the multiplication 
of pathogenic mycobacteria and their distribution within the host[19]. 
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2.1.4.2. Wax D fraction 
To conclude on the complexity of the cell envelope and its components it is worthy to 
mention the Wax D fraction, an active glycolipid present in all mycobacterial 
species[4,11,14]. These glycolipids are responsible for adjuvant activity which causes 
delayed-type hypersensitivity (DTH) which is due to mycobacterial proteins that cause the 
destruction of non-activated macrophages and the production of humoral antibodies[21]. The 
Wax D elicit granulomatous lesions and contribute to organism virulence[14,21]. 
 
2.1.4.3 Sulfolipids 
These are the third group of mycobacterial lipids that inhibit lysosome fusion to the 
phagocytic vacuole and suppress the production of superoxide anion, permitting 
mycobacteria to survive and multiply within the macrophages[5]. Mycobacteria present in 
developing lesions are able to survive under conditions of low pH, high lactic acid and high 
CO2. To date no virulence genes have been defined and disease manifestations results 

















Figure 2.2 General cross sectional area of mycobacterial cell wall/cell envelope structure [22]. 
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2.2 EPIDEMIOLOGY OF TUBERCULOSIS AND NTM INFECTIONS 
Globally, the current number of incident Tuberculosis (TB) cases was estimated to be 8.6 
million in 2012, with 16.2 million prevalent cases of TB disease and 1.3 million deaths giving 
an overall case fatality rate of 23% [23]. Among these deaths, an estimated 170 000 were due 
to MDR-TB[23]. The World Health Organisation (WHO) estimated that approximately one 
third of the world’s population is infected with M.tuberculosis(MTB)[23]The global 
prevalence of MTB infection was estimated to be 32% with 0.18% of the world’s population 
dually infected with MTB and HIV [19]. Global incidence rates increased by 0.4% per year 
between 1997 and 2000[19] (Figure 2.3). 
 
Sub-Saharan Africa has the highest incidence rate of TB of 300 per 100 000 population 
(Figure 2.3) South Africa (SA) is one of the twenty-two high-burden countries identified as 
having more than 80% of the new cases of TB worldwide and is reported to have the third 
highest TB burden in the world after India and China [19,24]. SA alone has over 2 million 
HIV-TB co-infected individuals [25,26]. KwaZulu-Natal is the leading province with high 
rates of TB as well as a high burden of MDR-TB[27]. Recently there has been an increase in 
the number of patients with extensively drug resistant (XDR) TB, which is defined as MDR-
TB together with resistance to one or more quinolones and an injectable 
aminoglycoside[28,29].Recently, the HIV epidemic has tremendously influenced the 
epidemiology of NTM disease in the African continent with reports from studies conducted 
in South Africa reporting an extremely high rate of NTM infections. 
 
Sputum samples obtained from 1196 people in the Zulu community in Natal, South Africa 
were examined for the presence of mycobacteria by microscopy and culture[30]. 
M.tuberculosis was detected in 9 samples and NTM was detected in 17 samples by culture, 
translating into prevalence rates of 750 per 100,000 for M.tuberculosis and prevalence rates 
of colonization/infection for NTM of 1,400 per 100,000[12]. Another study was conducted in 
South Africa on a cohort of HIV-negative gold miners[31]. They were investigated for the 
presence of mycobacterial disease between 1993 and 1996. The two most common organisms 
causing infection were M.kansasii and M.scrofulaceum with NTM rates of 66 and 12 per 
100 000 respectively[31]. The overall NTM rate was 101 per 100 000 with MAC making up 
only 6% of all the isolates[31]. However when another cohort of HIV - positive gold miners 
were investigated, the NTM rates (per 100 000) were much lower at 37 and 8.8 for 
M.kansasii and M.scrofulaceum respectively[26]. 



















Figure 2.3 Global TB incidence rates (per 100,000 population per year) at the start of 2000. (A) All forms of 





2.3 CLINICAL DISEASES ASSOCIATED WITH MYCOBACTERIA 
Members of the Mycobacteriaceae family are responsible for a wide range of diseases in 
humans and lower animals[12]. In humans these diseases, range from superficial self-limited 
infections of the skin caused by M. marinum, to pulmonary disease caused by both 
M.tuberculosis and by NTM[11]. Other infections include lymphatic infections, skin and soft 
tissue infections, infections of bones and joints and disseminated disease 
[5,16,32,33].M.bovis, M.avium, M.kansasii, and M.intracellulare all may produce a 
pulmonary disease in humans that may be indistinguishable from that caused by 
M.tuberculosis(Table2.1)[11]. Furthermore, skin and lymph gland infections caused by 
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M.tuberculosis can also be produced by other mycobacteria such as M.scrofulaceum, 
M.ulcerans and M.marinum. 
Table2.1 Clinical Disease associated with Mycobacteria 
Mycobacteria Clinical Disease 
M.tuberculosis pulmonary disease, skin and lymph gland infections 
M.bovis pulmonary disease 
M.avium pulmonary disease 
M.kansasii pulmonary disease 
M.intracellulare pulmonary disease, 
M. intracellulare-avium Complex (MAC) 
pulmonary disease, disseminated disease, 
tenosynovitis 
M.scrofulaceum skin and lymph gland infections 
M.ulcerans skin and lymph gland infections 
M.marinum skin and lymph gland infections, tenosynovitis 
M. fortuitum skin and soft tissue infections, osteomyelitis 
M. abscessus skin and soft tissue infections, osteomyelitis 
 
 
2.4 PATHOGENESIS AND TRANSMISSION 
Pathogenicity is defined as the complex of factors required to establish a successful human 
infection and includes the damage induced by such an infection[34]. The pathogenesis of 
tuberculosis represents a series of battles between the host and the tubercle bacillus[5]. Host 
defences include: an activated macrophage i.e., a phagocyte that inhibits an ingested tubercle 
bacilli and the ability of the host to stop intracellular replication of bacilli in non-activated 
macrophages[17]. This is achieved through destruction of the macrophages resulting in solid 
caseous tissue formation[5]. The defences of the bacillus depend on the following: 
i) The ability to multiply logarithmically within monocytes that emigrate from the blood 
stream to tissues at the site of infection. 
ii) The ability to multiply extracellularly in liquefied caseous material within 
cavities[5,11].  
Chapter 2  Literature Review 
15 
In a primary infection (individuals encountering the organism for the first time), 
M.tuberculosis enters the alveoli of exposed humans in an aerosol droplet where its first 
contact is thought to be with resident macrophages[5,11,17,35]. Infected macrophage cells 
migrate through the lymphatics to the hylar lymph nodes inducing an immune response 
dominated by T-helper cells. Inflammation will be present at the site of infection, along 
lymphatic channels and in the regional lymph nodes[5,17,34]. The defences of the immune 
system prevent proliferation of the organism and inhibits local spread of the bacilli [17]. 
Macrophages activated by T cells, kill the bacilli and slow down growth. The cell mediated 
immune response (CMI) which is detectable 2-8 weeks after an infection, is mediated by Th1 
helper cells and promotes protective immunity. However it is also responsible for localised 
pulmonary disease[5,17,35]. In the hylar lymph nodes, the organism are contained in 
tubercles which are small granulomas consisting of epithelioid cells, giant cells and 
lymphocytes. Over time the centres of the tubercle become necrotic and advance to form 
caseous material[35]. A Ghon complex can be defined as a combination of a single lesion in 
the lung and caseation in the bronchial lymph node.  
Although primary tuberculosis may be mild and asymptomatic, it may still take two courses 
(Figure 2.4). In healthy individuals the lesions heal spontaneously and become fibrotic or 
calcified. This can be seen in 90% of the cases. These lesions persist and can be seen after 
many years in chest x-rays. However in 10% of cases, particularly in immunocompromised 
individuals, the bacilli may invade the bloodstream and spread to the organs. This may lead 
to a fatal infection known as disseminated military tuberculosis[17,35]. With time, cellular 
immunity to the organism develops. Intracellular growth of the organism can be inhibited by 
the macrophages that have become activated by lymphokines produced by T lymphocytes. In 
the first two years after an infection, the risk of primary infection developing into clinical 
tuberculosis is at its highest[36,37]. 
Reactivation of dormant mycobacteria followed by the development of chronic, necrotic and 
progressive symptoms characteristic of tuberculosis is defined as secondary tuberculosis. 
Flare up can be due to impairment of the immune function, chemotherapy, malignancy, 
extensive corticosteroid therapy, immune- suppression caused by HIV and failure of the T-
cell macrophage immune system may render a person vulnerable to reactivation of latent 
mycobacteria[38,39]. Reinfection with externally acquired tubercle bacilli may lead to the 
same manifestation [17,35]. Secondary tuberculosis occurs at the apex of the lung due to the 
greater level of oxygenation for the promotion of growth[17]. Lesions become necrotic, 
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caseate and merge into larger lesions. Caseous lesions liquefy and contents discharged into 
the bronchi. Proliferation of the organism occurs in a well aerated cavitary. The disease 
rapidly progressives when organism are spread to other parts of the lung through the 

























Figure 2.4 Pathogenesis of tuberculosis. Adapted from Mechanisms of Microbial Disease[17]. 
The route of entry for NTM strains to get into the body includes the gastrointestinal or 
respiratory mucosal membranes[5,38-40]. However, in HIV-infected patients the 
gastrointestinal tract serves as an entry point [5,38]. MAC can survive in the normal gastric 
acidity and are taken up by the enterocytes of the terminal ileum [11]. The ability of MAC to 
use fibronectin to join bacteria to integrin receptors on mucosal cells is made possible by 
fibronectin-attachment protein [11]. A change in the MAC phenotype while it is inside the 
epithelial cell allows it to withstand the antimicrobial properties of the macrophage after exit 
[5,38]. MAC spreads to the intestinal lymph nodes in acquired immune deficiency syndrome 
(AIDS) patients and it can disseminate easily if host defences deteriorate [5,36]. NTM that 
are inhaled from dust or other aerosols are dealt with by the innate host defences mainly by 
mucociliary clearance and cough [5,35,41]. Excessive secretions in tracheobronchial passages 
promote bioflim formation which is a characteristic feature of NTM. NTM that spread to the 
alveolar spaces colonise Type 2 alveolar cells and alveolar macrophages [5,16,17]. NTM are 
able to survive inside the cells by interfering with fusion of phagosomes and lysosomes. CD4 
lymphocytes and natural killer (NK) cells can interact with infected mononuclear cells and 
kill the bacteria. This is normally observed in immunocompetent individuals. 
 
2.5 TREATMENT OF MYCOBACTERIAL DISEASE 
Currently the standard and optimal treatment for tuberculosis disease comprises of an initial 
intensive phase consisting of isoniazid (H), rifampicin (R), pyrazinamide (Z) and ethambutol 
for 2 months followed by a continuation phase of H and R for 4 months[42,43]. This 
preferred regimen forms the basis of the standard treatment of tuberculosis and is referred to 
by clinicians as 2HZR/4HR[19,42,43]. The success rate of the preferred treatment regimen 
can be seen in a bacteriologic conversion rate of close to 100% and a relapse rate of 
approximately 3-5% in patients with drug-susceptible TB.Approximately 10 drugs have been 
approved by the United States Food and Drug Administration (FDA) for treatment of 
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tuberculosis. Although fluoroquinolones are used to treat TB caused by drug resistant 
organisms, these drugs are not approved by the FDA for the treatment of tuberculosis. Table 
2.2 shows the first line chemotherapeutic agent used in the treatment of tuberculosis. 
Table 2.2 First line chemotherapeutic agents used in treatment of Tuberculosis. Adapted from Handbook of 
Tuberculosis, Clinics, Diagnostics, Treatment and Epidemiology[43]. 




Nicotinic acid hydrazide. 
Bactericidal. Inhibits mycolic 
acid synthesis most effectively 
in dividing cells.Hepatically 
metabolized. 
 
Regular dose:300mg or 
5mg/kg. 
High dose: 900mg or 
15mg/kg 
Administer with pyridoxine 
150-300 mg 
 
Hepatitis.l0-20% of patients have 
elevated transaminasesperipheral 
neuropathy 
Less common: fever, GI upset 




Bactericidal, Inhibits protein 
synthesis by blocking mRNA 
transcription and synthesis 
Hepatically metabolized. 
 
600mg or 10 mg/kg  
 
Incidence of adverse reactions: < 4% 
orange colored bodily secretions 
common less common: GI upset, 
hepatitis 
rare: fever, fatigue, cholestatic 
jaundice hemolytic anemia, 





Bactericidal. Effective in acidic 
environments e.g.cavitary 
disease. Hepaticallymetabolized 






Less common: GI upset, impaired 
diabetic control 





Bacteriostatic. Inhibits lipids 





Incidence of adverse reactions < 2%. 
Less common: GI upset, headache, 
malaise, arthralgia. 
Rare:dizziness, fever, peripheral 




Although approved for use in the treatment of Mycobacterium avium complex (MAC) disease 
in HIV infections, rifabutin and rifapentineare also used for the treatment of TB in patients 
who are experiencing severe drug interactions or intolerance with rifampicin[5,12,42,44]. 
Therapy used for the treatment of NTM infections differs significantly from the approved 6 
month treatment for MTB. Treatment forNTM is not only species dependent but is also 
influenced by immune characteristics and clinical manifestations of the infection [12,37,45-
47]. Species specific identification is crucial since mycobacteria are intrinsically resistant to 
most common antibiotics [12]. M.tuberculosis is intrinsically resistant to macrolides whilst 
NTM are resistant to first-line antituberculosis drugs[47]. In addition to the above, extended 
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therapy with a long duration is always necessary since mycobacteria are slow 
growing[12,39,48]. In HIV negative adults infectedwith MAC,treatment duration should 
continue until the patient is culture negative for 10 to 12 months [12,16,49]. Agents with 
proven clinical significance for MAC treatment include a whole range of antibiotics (Table 
2.3). 
Table 2.3 Antimicrobial Agents used for the Treatment of MAC Infections[5,12]. 
Drug Common Side Effects 
  
Azithromycin Diarrhoea, nausea, abdominal pain, rash, elevated hepatic 
transaminases,tinnitus, hearing loss  
Clarithromycin Diarrhoea, nausea, abnormal taste, abdominalpain, dyspepsia, elevated 
hepatic transaminases,QT prolongation 
Ethambutol Decreased visual acuity 
Rifampin Diarrhoea, nausea, abdominal pain, rash, elevated hepatic transaminases 
Rifabutin Abdominal pain,nausea,rash,arthralgias,uveitis,leukopenia,elevated hepatic 
transaminases 
Amikacin, Streptomycin Vestibulotoxicity, cochlear toxicity,nephrotoxicity, rash, fever, 
neuromuscular blockade 
Ciprofloxacin, Gatifloxacin, Levofloxacin, 
Moxifloxacin 
Nausea, vomiting, abdominal pain, rash, abnormal liver transaminases, 
tendonitis, QT prolongation 
Clofazimine Abdominal pain, diarrhoea, nausea,vomiting,skin discoloration, rash, dry 
skin, conjunctival and corneal pigmentation 
Linezolid Diarrhoea, nausea, headache,myelosuppression,lactic acidosis,optic 
neuropathy,peripheral neuropathy 
Mefloquine Dizziness,myalgia,nausea,vomiting,headache,rash,hair loss,sleep 
disorders,psychosis, elevated hepatic transaminases 
 
 
2.6 MECHANISMS OF DRUG RESISTANCE 
Mycobacteria, like most bacteria have developed efficient means to prevent unwanted 
metabolites from entering the cell[18,50].The presence of a highly hydrophobic nature of the 
mycobacterial cell envelope can serve as an effective permeability barrier to many 
antibiotics[18,51-53]. As a result mycobacteria may be intrinsically resistance to important 
first and second-line antitubercular drugs. Alternatively several strategies have been 
employed by bacteria to develop resistance to antibiotics. These include target modification, 
target overexpression, barrier mechanisms, drug inactivating enzymes and inactivation of 
drug inactivating enzymes[43,50]. Target modifications in mycobacteria, particularly 
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M.tuberculosis includes mutations in the inhA, rpoB, rrs, rpsL,emrB and gyrA 
genes[5,17,18,50]. These mutations are associated with isoniazid (INH), rifampicin (RIF), 
kanamycin (KAN), Streptomycin (SM), ethambutol (EMB) and fluroquinolone resistance 
respectively. Inactivation of drug activating enzymes due to mutations in thekatG, pncA and 
ethA/etaA also contribute to INH, PZA and ETH resistance respectively [5,18,52,54].  
However, in NTM, the absence of the erm37 gene allows for a natural susceptibility to 
macrolide therapy. Despite macrolide susceptibility, pre-exposure to macrolides also induced 
macrolide resistance due to the induction of related erm genes particularly erm38 and erm39 
in rapidly growing mycobacteria[55,56]. 
The exposure of mycobacteria to suboptimal concentrations of drugs in vivo leads to the 
selection of drug resistant mutants. Spontaneous generation of mutants resistant to INH and 
RIF occurs at a frequency of 1:1 million and 1:100 million respectively [5,50]. Ultimately, 
poor patient compliance to therapy and the use of an inappropriate treatment regimen for the 
lengthy 6-month duration have contributed to the global emergence of drug-resistant 
tuberculosis. This poses a major challenge for effective treatment and control. 
 
2.7 LABORATORY DIAGNOSIS OF MYCOBACTERIA 
Since the emergence of drug resistant tuberculosis in South Africa in 2006, there has been an 
urgent need for effective tuberculosis treatment programmes through the initiation of cheaper 
and rapid diagnostic tools. The extremely rapid progression of mycobacterial infections 
caused by M. tuberculosis and MAC in HIV-positive individuals has warranted the 
development of rapid methods for mycobacterial species identification and drug susceptibility 
testing[13,19]. Current conventional methods for the identification of mycobacterial isolates 
to a species level takes approximately 4-6 weeks and consist mainly of microscopy, culture 
growth characteristics and biochemical tests[42,45]. Although culture remains the “gold 
standard” for the detection of M. tuberculosis in routine diagnostic laboratories in South 
Africa, culturing methods are time consuming and delays the diagnosis of tuberculosis 
disease[45]. Further delays can occur when culture based drug susceptibility testing (DST) is 
used to monitor growing rates of drug resistance. [57]. The use of automated liquid culturing 
systems such as the Bactec MGIT 960 system (Becton Dickinson, Sparks, Md.) have speeded 
up the diagnostic process of M. tuberculosis[58] by reducing the detection rate to 5-10 days. 
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The development of new standardised tests for the detection of mycobacteria is imperative 
since treatment is species dependent. Since traditional identification approaches are unable to 
identify new emerging species, more robust and flexible diagnostic tests are required. This 
will also enable scientists and researchers to manage disease epidemics throughout the 
world[59]. The preceding sections will briefly discuss some of the conventional diagnostics 
methods employed in a routine diagnostic tuberculosis laboratory 
2.7.1 Smear Microscopy 
The discovery of the microscopic staining of the tubercle bacilli in 1882 by Robert Koch, has 
led to this technique becoming the most basic and most common tool used for the phenotypic 
confirmation of acid fast bacilli (AFB) in biological samples[13]. In resource poor settings 
with a high burden of TB, microscopy is a widely used diagnostic technique and remains a 
mainstay both for the diagnosis of TB and for the monitoring of treatment progress. Although 
this method has a low sensitivity (50-60%), it is inexpensive and simple [13,43,60]. The 
conventional gram staining methods are ineffective for the staining of mycobacteria since the 
high lipid content of the mycobacterial cell wall acts as an impermeable barrier for commonly 
used aniline dyes[20,60]. In order to address the problems with poor retention and adsorption 
of basic staining dyes, the auramine O and the Ziehl-Neelsen (ZN) stain have been widely 
adopted for the microscopic detection of mycobacteria[18]. Smears for AFB detection are 
prepared directly from untreated or concentrate clinical specimens[19].  
 
The affinity of the mycolic acid in the cell walls for the fluorochromes enables the auramine 
stain to stain the bacilli bright yellow against a dark background[4]. This can be viewed using 
a fluorescence microscope with 40 X lower magnification (Figure 2.5). Ziehl-Neelsen stained 
acid-fast bacilli appear pink against a blue background when observed under the light 
microscope, as shown in Figure 2.5. Results from a smear examination normally includes a 
measure of quantity, such as actual number of bacilli seen per field[19].A major disadvantage 
of smear microscopy is that non-viable or dead bacilli will fluoresce when stained with the 
auramine O stain and dead cells will be stained by the ZN stain. As a result not all smear 
positive cases are culture positive. In HIV positive individuals false positives due to the 
presence of NTM can be an issue since smear microscopy cannot speciate[5,18]. Conversely, 
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HIV-positive patients with an impaired immune response may have reduced rates of 
cavitation and as a result reduced numbers of mycobacteria may be present in their sputum 
sample as compared to HIV-negative TB patients. NTMs particularly the rapid growing 
mycobacteria (RGM), may be more sensitive to the AFB decolourization procedure and may 















Figure 2.5 Microscopic visualization of stained Mycobacterium tuberculosis with Ziehl-Neelsen (right) and 




Mycobacterial culture on either solid or liquid media is considered to be the gold standard 
method for the identification of mycobacteria and is able to distinguish M. tuberculosis from 
some of the NTM[61]. Culture can be used on biopsy material and needle aspirates and 
unlike smear microscopy it is widely used for the diagnosis of extra-pulmonary or 
paucibacillary TB[43]. Unlike smear microscopy with a limit of detection of approximately 5 
x 103 to 1x104 bacilli/ml, a few as 10 viable bacilli can be detected by culture[19]. Culture is 
more demanding in terms of expertise and laboratory infrastructure than smear microscopy 
and is largely restricted to a reference laboratory. A major limitation of culture is that it is 
time consuming requiring more than 4 weeks in obtaining a conclusive result from solid 
media[61]. 
 
Solid media can be either agar based or egg-based. Middelbrook 7H10 and Middelbrook 
7H11 are the two most commonly used agar based media whilst Lowenstein-Jensen (LJ) is a 
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commonly used egg-based media[5,19]. These media differ in their chemical composition 
and formulation. Several commercially available liquid culturing systems namely the Bactec 
460 and 960 systems (Becton Dickinson, USA) have been developed to reduce the time to 
detection of growth (TTD)[19,43]. These systems are sophisticated and are able to detect the 
presence of actively dividing bacilli by measuring either the excretion or consumption of 
metabolic products and are not dependent on appearance of visible growth as observed by the 
solid culture process. Cultures in broth media have a higher yield of mycobacteria and 
produce more rapid results than those on solid media even thoughthe contamination rate was 
found to be statistically higher [12,62]. There are several advantages of using solid media. 
These include the ability to observe colony morphology, growth rates, more than one 
mycobacterial species (mixed species), and quantitation of the infecting organism[12]. Solid 
culture method requires a skilled microscopist as in the case of sputum smears. Furthermore, 
fastidious NTMs such as M. genavense, M. avium subsp. paratuberculosis and M. ulcerans 
require special supplementation for recovery on culture [12]. 
 
2.7.3 Biochemical Tests 
The preliminary classification of mycobacteria, particularly NTM is achieved using growth 
rates. NTMs have also been traditionally classified into 3 groups based on the production of 
pigments. The use of pigment production may not be useful for final species identification; 
however it may be beneficial for narrowing the possibilities[4,5]. Although growth 
characteristics are seldom used for the definitive diagnosis of mycobacteria, the presence of 
pigmentation and smooth colony morphology can exclude the isolate as belonging to the M. 
tuberculosis complex[12,60]. As mentioned previously, M. tuberculosis complex form non-
pigmented and rough colonies. In addition to culture, various biochemical tests such as 
niacin accumulation, reduction of nitrates to nitrites, tween 80 hydrolysis, catalase activity, 
arylsulfatase activity, urease activity, pyrazinamidase, iron uptake and growth inhibition by 
thiophene-2-carboxylic acid hydrazide are available for mycobacterial species identification. 
The discrimination of M. tuberculosis and M. bovis can be achieved by using just four 
biochemical tests. M. tuberculosis is niacin and nitrate positive, resistant to 5ug of 
thiophene-2-carboxylic acid hydrazide (TCH) per ml incorporated into 7H11 agar and is 
positive for a pyrazinamidase test[19]. All of these tests are reversed for M. bovis. However, 
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the identification using conventional biochemical analysis is both time consuming and 
increases the turnaround time, leading to significant delays in diagnosis. Of note, testing for 
NTM usually requires a series of biochemical tests based on growth rate. These tests can be 
quiet labour intensive and complicated. It has been shown that isoniazid resistant MTB 
strains may be negative for both the niacin and nitrate test[19]thus resulting in false 
negatives. Furthermore MTB may be negative for the pyrazinamidase test particularly in 
patients who have been treated with pyrazinamide (PZA) and have developed PZA 
resistance[13,19,43]. 
2.7.4 Drug Susceptibility Testing (DST) 
The rapid detection of drug resistance organisms is crucial for the management of 
tuberculosis disease. There are several methods for phenotypic drug susceptibility testing. 
These include the proportion method, the resistance ratio, and the absolute-concentration 
method[19]. The resistance ratio measures the Minimum Inhibitory Concentration (MIC), the 
lowest concentration of the drug capable of inhibiting growth of the organism, compared to 
the MIC of the reference M. tuberculosis 25177 strain[63]. A value of 2 or less derived from 
the resistance ratio measures indicates susceptible whilst a value of 8 and above indicates 
resistance. Susceptibility testing using the agar method is robust and can be used to tests both 
first and second line anti-TB drugs. These methods require an adequate infrastructure 
andcannot be implemented in resource poor settings. 
Current in vitro susceptibility methods using rifampicin and ethambutol may not be reliable 
when used for the testing of MAC. MAC has limited in vitro susceptibility and clinical 
response has been shown to correlate only with macrolides.M. abscessus and M. simiae have 
limited in vitro susceptibility and as a result there is limited data for a correlation between the 
clinical response in the treatment of pulmonary disease by an antimicrobial and in vitro 
susceptibility testing[12]. According to Clinical Laboratory Standards Institute(CLSI), a 
broth-based method particularly microdilution and macrodilution methods are recommended 
for the susceptibility testing of slow growing mycobacteria such as MAC [3,12,64]. These 
methods are not available in resource poor settings. For less commonly isolated NTMs such 
as M. malmoense, M. xenopi, and M. terrae, there is no specific susceptibility method. 
Antimycobacterial MIC testing for isolates of M. chelonae and M. abscessus using imipenem 
may be problematic due to a lack of reproducibility. 
 
2.7.5 Mycobacteriophage-based tests 
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Mycobacteriophage-based assays are proving to be useful tools for the identification of viable 
bacilli as well as for antimicrobial susceptibility testing[65,66]. These methods have been 
incorporated in two methods, the FASTPlaque TB-RIF test (Biotech Laboratories, Ipswich, 
United Kingdom) and the luciferase reporter phage (LRP)[19]. Both assays are based on the 
ability of the viable M tuberculosis bacilli to protect infecting mycobacteriophages from 
chemical inactivation and to facilitate the replication of infecting phage[67]. The 
FASTPlaque TB-RIF test (Figure 2.6) uses a mycobacteriaphage that is added to 
decontaminated sputum samples or culture suspension[19]. After an overnight incubation, the 
external phages that did not infect the host cells are destroyed using a virucidal solution. 
Phages that proliferate within mycobacterial cells are detected when the phage-infected 
pathogen suspension is mixed with rapidly growing M. smegmatis[19]. The phages released 
from the lysed M. tuberculosis infect the M. smegmatis cells. They replicate and amplify in 
the helper cell host (M. smegmatis). The progeny phages undergo cycles of infection and 
replication resulting in lysis of the mycobacteria. This can be seen as clear plaques in a lawn 
of helper cells. According to Mani et al., 2003, the number of plaques generated is directly 
proportional to the number of viable M. tuberculosis cells that were in the original 
sample[68]. 
Rifampicin resistantM. tuberculosisstrains can be detected within 48 hrs using 
mycobacteriophage-based assays[69]. The number of plaques in a rifampicin-free control is 
compared with the number of plaques produced from a sample incubated in the presence of 
rifampicin. A sensitive strain can be observed when there is an absence of plaques from the 
rifampicin containing sample. In this case the tubercle bacilli are nonviable and cannot 
support phage replication. The presence of plaques in the rifampicin-containing sample 
indicates rifampicin resistant strains that are viable and are able to support phage replication. 
It several studies, the FASTPlaque TB-RIF assay correlated very well with the BACTEC 460 
for the detection of rifampicin susceptibility in M tuberculosis cultures. In a study conducted 
by Eltringhamet al.,1999, the phage assay was compared to the (Real-Time) RT-PCR for the 
detection of rifampicin resistance[67]. When compared to the resistance ratio method, the 
phage assay showed a good concordance of 100%, whilst the RT-PCR showed a sensitivity 
of 97% (35 of 36) for the diagnosis of rifampicin resistant isolates[5]. Currently there is no 










Figure 2.6 FASTPlaque TB-RIF test showing the ability of the viable M tuberculosis bacilli to protect 
infecting mycobacteriophages from chemical inactivation by Virusol treatment and to facilitate the replication of 
infecting phage[70]. 
2.7.6 Microplate Assays 
Several colorimetric methods have developed for the detection of drug-resistant M. 
tuberculosis. These methods utilize oxidation-reduction indicators for the detection of 
mycobacterial growth in the presence of antituberculosis drugs[71,72]. Alamar blue, 
resazurin(Figure 2.7) and tetrazolium bromide are some of the indicators that can be added to 
microplates containing antibiotics of increasing concentrations and pure cultures of isolates. 
After 5 to 7 day incubation of the microplate, growths can be recognised as a change in the 
colour of the indicator due to the reaction of the dye. The minimum inhibitory concentration 
(MIC) of each drug can be determined by the change of colour in the wells. Since the 
indicators are added 5-7 days after growth, one of the main concerns with this type of testing 
is biosafety. The microscopic observation drug susceptibility (MODS) testing is a microplate 
assay which has less biosafety risk, uses critical drug concentrations and measures growth by 
microscopic reading[19,72]. According to Palomino et al.,2002 the agreement for rifampicin 
and isoniazid when comparing the MODS assay with the agar proportion method and the 
alamar blue assay was found to be 100% and 89% respectively[73]. Of note, microplate 













Figure 2.7 Resazurin microplate assay. A change to pink indicates reduction of resazurin and therefore 
bacterial growth. The MIC is defined as the lowest drug concentration that prevents colour change [73]. 
 
2.7.7 Molecular Testing 
 
A number of in-house and commercial available amplification methods have been developed 
for the detection and identification of mycobacteria directly in the patient’s specimen. In the 
last decade, there have been numerous studies published on the ability of nucleic acid 
amplification assays (NAAs) to directly detect M. tuberculosis in clinical specimens. Of note, 
the U.S Food and Drug Administration (FDA) have approved some of these commercially 
available assays for the diagnosis of M. tuberculosis complex (MTBC) in clinical specimens. 
These polymerase chain reaction (PCR) based assays include the amplified M. tuberculosis 
direct test (MTD) (Gen-Probe, Inc., San Diego, California), the AMPLICOR M. tuberculosis 
test (Roche Molecular Systems, Branchburg, N.J) (STC) and the ProbeTec Direct TB which 
is a strand displacement amplification (SDA) test by Becton-Dickinson[19]. The first 
molecular tests were introduced in the 1980s for the rapid discrimination of MTBC and NTM 
(Gen-Probe, San Diego, California, USA) in smear positive sputum samples[12]. The 
AccuProbe DNA hybridisation assay became available for the identification of most 
commonly encountered mycobacteria such as MTBC, M. avium complex (MAC), M. avium, 
M. intracellulare, M. kansasii and M. gordonae. In KwaZulu-Natal (South Africa), 
researchers announced the emergence of resistant TB strains not only to isoniazid, and 
rifampicin but also to at least three classes of second line-drugs[29]. This form of resistant 
TB became known as extensively drug-resistant tuberculosis (XDR-TB). This has led to an 
unprecedented level of interest on the development of new molecular tools for rapid 
diagnosis of M. tuberculosis. In 2008, the World Health Organisation approved the Genotype 
MTBDR Plus assay (Hain-Lifesciences,Nehren, Germany) for the rapid genotypic detection 
of M. tuberculosis and its resistance to isoniazid and rifampicin in smear positive sputum 
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samples. Subsequent to this, the Gene-xpert (Cepheid, USA) was approved in 2009 for the 
screening of patients suspected of M. tuberculosis disease. 
 
2.7.7.1 Genotype MTBDR Plus, MTBDRsl, CM and AS Assays 
A commercially available Genotype MTBDR Plus assay (Hain-Lifesciences, Nehren, 
Germany) has been developed for the simultaneous and rapid identification of 
Mycobacterium tuberculosis isolates and drug susceptibility testing against rifampicin and 
isoniazid from smear-positive and smear negative, culture positive clinical specimens. These 
assays are based on reverse hybridization of a PCR product to a nitrocellulose strip with 
immobilized probes for different mycobacterial species. The rpoB, katG, and inhA are the 
genetic loci targeted in this assay to identify gene mutations. The ability of the assay to 
determine significant mutations within the rpoBgene (coding for the b-subunit of the RNA 
polymerase) allows for the detection of rifampicin resistance. For high level isoniazid, the 
katGgene (coding for the catalase peroxidase) is assessed and for testing of low level 
isoniazid resistance, the promoter region of the inhAgene (coding for the NADH enoyl ACP 
reductase) is assessed for significant mutations[74]. 
A commercially available Genotype MTBDRsl assay (Hain-Lifesciences, Nehren, Germany) 
has been developed for the simultaneous rapid identification of Mycobacterium tuberculosis 
isolates and drug susceptibility testing against fluoroquinolones (ofloxacin and 
moxifloxacin),aminoglycosides/cyclic peptides (capreomycin, viomycin/ kanamycin, 
amikacin) and ethambutol from smear-positive and smear negative, culture positive  clinical 
specimens. The gyrA, rrs, and embB are the genetic loci targeted in this assay to identify gene 
mutations. Resistance to fluoroquinolones, aminoglycosides and ethambutol in 
M.tuberculosisis most frequently associated with mutations in the gyrA, rrs, and embB genes 
respectively[75]. Good correlations were observed between the detected mutations and 
resistance phenotypes. By targeting mutations in codons 90, 91, and 94 in the gyrA gene, 
approximately 70-90% of all fluoroquinolone-resistant strains could be identified[75]. 
Mutations A1401G, C1402T, and G1484T in therrs gene have been linked to amikacin, 
capreomycin and kanamycin resistance, with each responsible for a specific resistance 
pattern[76]. Mutations G1484T and A1401G were found to cause high level resistance to all 
drugs, whereas C1484T causes resistance to only capreomycin and kanamycin[76]. Mutations 
at codon embB306 are found in 30% to 68% of ethambutol-resistant clinical strains. 
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The MTBDRsl strip consists of 3 gyrAprobes [wild-type 1(WT1), wild-type 2 (WT2), and 
wild-type 3 (WT3)] which represent the genes encoding amino acids 85 to 97. In addition to 
this, 6 additional probes (gyrAMUT1 A90V, gyrA MUT2 S19P, gyrA MUT3A D94A, gyrA 
MUT3B D94N/Y, gyrA MUT3C D94G,gyrAMUT3D D94H) target the most common 
mutations[76]. Both the wild type (WT) and mutant (MUT) areas on the strip allow for 
fluroquinolone resistance to be detected. Amikacin/ Kanamycin resistance are detected by the 
presence of four probes which cover the wild type region of rrs and the most common 
mutations. These are the rrsMUT1 and MUT2 which represent the amino acid changes 
A1401G and G1484T respectively. For ethambutol resistance wild type probeembB (WT1) 
targets the embB306 codon, while embB MUT1A and 1B are available to detect nucleotide 
exchanges ATG-ATA (M306I) and ATG-GTG (M306V). The omission of a signal for the 
wild type probe and/or the presence of a signal for the mutant probe will indicate the presence 
of a resistant strain. A negative control containing no DNA template is included with each 
run. 
The simultaneous execution of the GenoType Mycobacterium CM/AS assays (CM, common 
mycobacteria; AS, additional species), allows for the simultaneous identification of a variety 
of mycobacterial species by targeting the 23S rRNA gene[77,78]. Relevant M.tuberculosis 
complex can be distinguished from the members of the M. avium complex, M. kansasii, and 
M. chelonae. The Additional Species (AS) strip allows for the identification of less frequent 
mycobacteria namely M. simiae, M. mucogenicum, and M. celatum. The combined use of the 
CM and AS assays allows for the identification of 35 different mycobacterial patterns of 
which 23 represent single mycobacterial species, 8 patterns represent mixed mycobacterial 
species and the latter 4 patterns represent Mycobacterium species and gram-positive bacteria 
with a high GC content[77]. 
Another region of interest is the 16S ribosomal DNA (rDNA) which codes for a 1,500 
nucleotide sequence known as the 16S rRNA[12]. This is a highly conserved gene common 
to all mycobacterial organisms. It consists of a conserved region and regions with nucleotide 
variations (variable regions). Mycobacterial identification is based on two hypervariable 
sequences known as regions A and B. The introduction of 16S DNA sequencing has 
improved on the identification of mycobacteria. Identification not only became less time 
consuming, but also much more robust. NTM species identification of organisms such as M. 
kansasii and M. gastri as well as M.ulcerans and M.marinum is based on region A. Sequence 
of region B is only considered when identification based on Region B is not conclusive. For 
some isolates such as M.chelonae and M.abscessus differentiation cannot be accomplished 
within regions A and B even though their sequences vary by 4bp at other 16S rRNA[79]. 
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Overall, several molecular based methods have been proposed for the identification of NTM. 
These include the DNA probes or Accuprobe (GenProbe, San Diego,CA), sequencing of 
housekeeping genes, polymerase chain reaction restriction analysis based methods on 16S 
rRNA, rpoB, recA, 16S-23S rRNA internal transcribed spacer, hsp65 and tufgenes[38]. 
Routine molecular identification of mycobacteria using the above methods is simply based on 
single genetic traits. Hsp65 PRA methods have shown to be rapid and reliable for species 
identification[38]. However with the emergence and divergence of new species and sub-
species, 16S rRNA typing may not be able to discriminate species with highly similar 16S 
rRNA gene sequence. M. szulgaiand M.malmoenseare two distinct specieseven though they 
differ by two nucleotides. Molecular methods may not allow for an accurate discrimination of 
closely related species. On the other hand these methods are costly and cannot be 
implemented in resource poor laboratory settings often encountered in South Africa. 
Genotype PCR testing (Hain-Lifesciences, Nehren, Germany) consists of DNA isolation 
either from cultured material (culture plates/liquid medium) or direct materials (pulmonary, 
smear-positive, and decontaminated), multiplex amplification with biotinylated primers and 
reverse line hybridisation[75,77]. The hybridization process consists of chemical denaturation 
of the amplification products, hybridization of the single-stranded, biotin-labelled amplicons 
to membrane-bound probes, stringent washing, addition of a streptavidin/alkaline 
phosphatase (AP) conjugate, and an AP mediated staining reaction. An interpretation 
template ensures the easy and fast interpretation of the banding pattern obtained. 
 
Hybridization is initiated by denaturing the amplified double stranded DNA into single 
strands using 20ul of denaturing solution. Single stranded DNA is hybridized to membrane 
bound probes for 30min at 450C using pre-warmed hybridisation solution. Unbound 
amplicons are removed using a stringent wash solution. Several rinse solutions are used for 
washing off amplicons at 250C. Hybridised amplicons are chromogenically visualised using 
streptavidin conjugated with an alkaline phosphatase-biotin and a substrate buffer is added. 
At least two wash steps are required to stop the reaction.  
 
2.7.7.2 Gene-Xpert 
With the growing evidence of the MDR-TB epidemic, nucleic acid amplification tests such 
has the Gene-Xpert have had great promise in TB diagnosis and for the rapid detection of 
drug resistance.The GeneXpert MTB/RIF assay (Cepheid, USA) is a fully automated, 
cartridge based, hemi-nested real time-PCR systemand can diagnose M.tuberculosis and  
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rifampicin (RIF) resistance simultaneously using unprocessed clinical specimens[80]. Results 
are available within 2 hours, regardless of the sputum smear status. The molecular beacons 
are designed to only hybridize correctly with amplified wild type (RIF sensitive) rpoB 
sequences[81].Mutations in the 81 base pair (bp) region interferes in 2 ways with 
hybridization of these beacons; there is either delayed onset/partial inhibition or complete 
suppression of fluorescence in the corresponding molecular beacon.Rifampicin resistance is 
particularly suited to rapid molecular detection since 95% of all RIF resistant strains have 
mutations in 81 bp region of therpoB gene which encodes for the active site of bacterial RNA 
polymerase[81,82].TherpoB core region is flanked by MTB specific DNA sequences, thus it 
is possible to test for MTB and RIF resistance together by targeting a single amplicon 
generated using PCR technology[83]. It has been noted by previous studies that mutations in 
the 81 bp region of the rpoB gene are “highly” predictive of RIF resistance whereas 
susceptible isolates almost always have wild type nucleotide sequence[81].RIF resistance is 
strongly but not invariably indicative of MDR-TB. RIF mono-resistance is rare; 85-90 % of 
RIF strains are resistant to INH (isoniazid) as well[81].The sensitivity for detection of 
isoniazid resistance was 85% and 98% for the detection of RIF resistance[81].Thus, the rpoB 
gene is a better molecular target for diagnosing TB and drug resistance. The assay has 
advantages over the line probe assay in that it is not technologically demanding and it is 
conducted in a simple almost fully automated cartridge based system. This reduces cross 
contamination and decreases the risk of false positives as seen in other PCR based 
technologies. The simplicity for the operator could make the assay feasible to be 
implemented outside centralized laboratories and this could potentially impact on TB control. 
However, recent studies have come to light which questions the reliability of the GeneXpert 
MTB/RIF assay’s diagnostic ability. GeneXpert cannot be used as an MDR diagnostic tool 
since it is only used in the detection of RIF resistance and there are no means of detecting 
INH resistance.Line Probe Assay (LPA) has an advantage over the GeneXpert assay in that it 
detects both RIF and INH gene mutations. Therefore, this assay can accurately diagnose 
MDR-TB.Discrepancies between the GeneXpert and DST (Drug Susceptibility Testing) 
results regarding RIF resistance (false resistance) has been previously reported[84].Several 
studies have detected false positive RIF resistance results (over diagnosis).The presence of 
any mutation in the 81 bp region will be interpreted as the isolate being RIF resistant, 
irrespective if there are no sign of phenotypic resistance[84]. Several studies have shown 
false negative results by the GeneXpert (under diagnosis). Mutations that lie outside of the 81 
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bp region (5-10%) will not be identified by GeneXpert, leading to the isolate being 
interpreted as RIF susceptible[84]. 
 
2.7.7.3 IS6110-Based Methods 
The IS6110 is a transposable element and is the most widely used repeated sequence in 
strain identification methods. IS6110 is a 1.365-bp insertion sequence (IS) with a defined 28-
bp imperfect inverted repeat at the ends and a single PvuII restriction site. The IS contains 
an open reading frame (ORF) that codes for a transposase and is limited to the M. 
tuberculosis complex[19]. It has shown great potential for use in strain differentiation. On 
PvuII digestion of the chromosomal DNA, the IS6110 element is split into two domains, each 
attached to their respective adjacent genomic segment [43]. The restricted PvuII DNA is 
then electrophoretically separated on an agarose gel, Southern transferred to a nylon 
membrane and hybridised with a labelled probe complementary to the 3’-domain of the 
IS6110 [19,43]. Autoradiography is used to visualise the banding patterns and measure the 
number of IS6110 elements in their genome and their distance from their adjacent 
chromosomal 3’ PvuII restriction sites. The results obtained by testing a large number of 
strains in different settings allows for the understanding of the distribution and spread of 
M.tuberculosis infection during an outbreak. This allows for strains from different 
geographic areas to be compared and the movement of individual strains to be traced [85]. 
Such data may provide important insights into the global transmission of tuberculosis and 
identify strains with particular properties, such as high infectivity, high virulence, and/or 
multidrug resistance 
 
Although IS6110 genotyping methods shows the greatest discriminatory power and is 
regarded as the ‘gold standard’ for M.tuberculosis genotyping, it is cumbersome and time-
consuming technique, requiring large quantities of good quality DNA. Furthermore the 
discrimination power of the technique is dependent on the number of IS6110 elements 
present in the genome of the M. tuberculosis isolate. As a result more than six IS6110 
elements need to be present within the genome inorder for an epidemiological relationship 
to be inferred. Classification of strains with fewer copies requires secondary typing 
methods. 
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2.7.7.4 Direct-Repeat Locus-Based Methods 
Based on the initial genetic analysis of the M.bovis BCG (BacilleCalmette-Guerin), it was later 
shown that the DR locus is a single region of the M. tuberculosis chromosome that contains 
multiple copies of a 36-bp direct repeat region that is reiterated between 10 and 50 
times[43] (Figure 7). One DR and its neighbour spacer sequence are termed a direct variable 
repeat (DVR). Even though the overall arrangement of the spacers in the DR is conserved 
among strains, polymorphisms in this region arise from deletion/insertion of segments of 
the DR locus. A copy of the IS6110 is inserted into a specific site in one of the 36-bp repeats 
in all of the M.bovis (BCG) strains, M.bovis strains and M.tuberculosis strains. Strains of M. 
tuberculosis that lack IS6110 contain the DR locus. Spacer oligonucleotide typing 
(Spoligotyping) involves amplification of the DR locus by PCR. The specific primers 
(biotinylated) used are complementary to the DR sequence and directed outwards from the 
36-bp repeat, successfully amplifying the variable spacers and repeats present in a particular 
strain. Following amplification of the DR locus, the labelled PCR products are hybridised to a 
membrane containing the corresponding covalently bound oligonucleotides of the 43 
variable-spacer sequences present in M.tuberculosis strain H37Rv and M.bovis. Strains share 
various combinations of the variable spacers and are distinguished on the basis of their 
positive and negative signals for each spacer[19]. After performing spoligotyping on clinical 
samples and cultured isolates, results generated that display the absence of 5 spacers 
(numbers 38 to 43) enables M.bovis species to be determined. One of the limitations of 
spoligotyping is that polymorphisms in the DR locus do not discriminate 
M.tuberculosisstrains as well as RFLP of the IS6110. Stains with similar spoligotyping pattern 
may have different IS6110 patterns[19] . Another limitation of spoligotyping, is that it 




















Figure 2.8 The top section shows the 43 DR (rectangles) and spacers (horizontal lines) used in spoligotyping. 
The bottom section shows the spoligotypes of three strains. DR locus contains 10 to 50 copies of a 36-bp direct 
repeat, separated by spacer DNA with various sequences, each of which is 37 to 41bp. A copy of the IS6110 is 
inserted within a 36-bp DR in the middle of the DR locus in most strains. M.tuberculosis strains have the same 
overall arrangement of spacers but differ in terms of the presence or absence of specific spacers [86]. 
2.8 MASS SPECTROMETRY 
 
For the first time in 1897, a pioneering scientist JJ Thompson was able to measure the mass 
of an electrically charged particle known as an electron[87]. In his experiment the potential to 
separate charged particles based on a mass to charge ratio was demonstrated. Since the 
development of ‘Soft Laser Desorption’ (SLD) technology in 1987 by Koichi Tanaka and John 
Bennett, subsequent improvements were made by Franz Hillenkamp and Michael Krans[88] through 
the introduction of Matrix-Assisted Laser Desorption/Ionization (MALDI) [89]. The mass-to-charge 
(m/z) ratio of an electrically charged molecular or ion can be measured using a mass 
spectrometer[90]. The mass unit of measurement was expressed as Daltons (Da) and the 
magnitude of charge of the electron is indicated by the integer z. Therefore the mass to 
charge ratio (m/z) represents a Dalton per unit of charge of an ion. The fundamental 
components of a mass spectrometer consist of the following (Figure 2.8): 
a) An ion source  
b) A mass analyser  
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Figure 2.9 Fundamental components of a mass spectrometer[90]. 
 
The ion source allows for the vaporisation, ionisation and acceleration of sample analytes. 
Prior to analyses the samples are converted into the gas phase during the process of 
vaporisation. In conventional mass spectrometry vaporisation can be achieved through the 
process of simple heating. Ionisation on the other hand is accomplished by the use of 70eV 
electrons[90]. Both processes allow for the decomposition of the analyte. The ions are then 
separated according to their mass-to-charge (m/z) ratio by the mass analyser. Gas phase ions 
produced in the ion source are directed by either an electric or magnetic field into the mass 
analyser. As the ions pass through an electromagnetic field, separation to their mass to charge 
ratio is achieved through the presence of filters. In order to prevent collision or interference 
of ions with ubiquitous air molecules, ions move through a vacuum of 10-4torr or less[91]. 
However of concern is that the process of ionization by electrons accelerated through a 
potential of 70eV leads to possible fragmentation of the ion, leaving virtually little or no trace 
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of the parent ion[92]. Since mass spectrometry may have be carried out on parent ions rather 
than daughter ion species, the use of conventional mass spectrometry with excessive 
fragmentation from a ‘hard’ ionization process may not be conducive for the analysis of large 
biological molecules. The availability of a more ‘softer’ sample vaporisation and ionisation 
methods present in modern mass spectrometry has allowed for the analysis of compounds of 
biological origins (parent ions), ones with limited volatility and thermostability[91]. Modern 
mass spectrometry approaches such as the Matrix Assisted Laser Desorption/Ionization 
Time-of-Flight mass spectrometry (MALDI-TOF MS) provides a non-equilibrium energy 
transfer that can eject (desorb) samples into the gas phase in the absence of heating and utilise 
a low energy proton transfer for a ‘softer’ ionisation[90]. 
 
There are various types of ionisation methods available. For a ‘softer’ method, Matrix 
Assisted Laser Desorption/Ionization Time-of-Flight mass spectrometry (MALDI-TOF MS), 
Electronspray (ESI) andChemical Ionization (CI) are available for ionisation of relatively 
small volatile molecules, peptides, proteins and nucleotides[90]. The mass range that can be 
detected with these approaches include up to 0.5 kDa, 1 kDa and 200 kDa for MALDI-TOF 
MS, CI and ESI respectively[90]. A Fast Atom Bombardment (FAB) approach also offers a 
softer ionisation method however ionisation is harder than MALDI-TOF. Electron Impact 
(EI) offers a hard ionisation method for relatively small volatile molecules, up to 1 kDa. 
There are also various types of mass analysers that use magnetic/electric fields and 
dispersion/filtering for the separation of ions according to their mass-to-charge ratio[92]. 
Commonly used mass spectral analysers include: 
a) Magnetic Sector Analysers: Employs magnetic or an electric field to accelerate the 
charged ions. Ions of larger m/z are less deflected than ions of smaller m/z values 
resulting in dispersion of these ions in space. Changes of the magnetic field strength 
allow for a change in the trajectories of the bundles of ions. Ions separate according 
to their mass to charge ratio as they bend through the mass analyser [90].  
b) Time-of-flight Mass Analysers: Similarly charged ions emitted and accelerated in a 
brief burst (pulsed) travel with the same kinetic energy through a Time-of-flight tube 
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and their travelling time is dependent on their different m/z ratios. According to 
Frieden, et al.,2003 the ions separate according to their different molecular weight 
sizes with the smaller ions (m/z values) arriving first at the detector (83). 
c) A quadrupole mass filter: Applying a simultaneous constant direct current (dc) and 
radio frequency (rf) electric fields, mass sorting based on ion motions is achieved. 
Any changes in field strength such as potential difference allow ions of different m/z 
to be scanned through the mass analyser and transmitted to the detector [93]. 
d) Fourier Transform Ion Cyclotron Resonance (FR-ICR) Spectrometer: Molecular weight 
is measured through the detection of the image current produced by the 
accelerating ions in a magnetic field. 
e) Reflectron mass spectrometry analyser: Mass analyser uses the static electric field to 
reverse the ions in the opposite direction [93]. The ions are reflected back towards 
the source thereby increasing the maximum achievable resolving power by a factor 
of 2 [90]. 
 
As mentioned earlier, the third basic component of a mass spectrometry is the detector. The 
detector precisely measures the current released when an ion passes by or hits a surface. The 
mass-to-charge ratio of the ions allows for the generation of mass spectra which can be 
visualised on the computerised system. The various types of detectors used in mass 
spectrometry include electron multipliers, Faraday cups, ions-to-photon detectors and micro 
channel plate detector (MCP)[90]. All mass spectrometers are connected to computer based 
systems for the control, acquisition, storage and presentation of data. Computer-based 
software is available for the quantitation, spectral processing, interpretation and organism 














Figure 2.10 Schematic representation of the components of mass spectrometry[90]. 
 
In a MALDI-TOF MS system (Figure 2.10) both vaporisation and ionisation can be 
performed simultaneously in a single step. The use of soft ionisation method offered by 
MALDI-TOF MS allows for fragile bio-molecules to be analysed without any fragmentation 
or decomposition of these molecules[90,94]. A soft non-destructive ionisation process 
prevents fragmentation and the loss of spectra quality primarily due to a decline in resolution 
quality and complete loss of parent ion[89,95]. The conversion of solid phase sample analytes 
into gas phase ions allows for a softer non-destructive ionisation with minimal 
fragmentation[96]. Heat induced sample evaporation or vaporisation typically associated with 
conventional mass spectrometry differs from modern mass spectrometry. Unlike traditional 
mass spectrometry systems that utilise Electron Bombardment (EB) and Electron Impact (EI) 
for ionisation, MALDI-TOF MS on the other hand allows for samples in a high vacuum (10-
6torr) to sublime directly into the ion source with minimal heating[90]. Furthermore, 
ionisation within a MALDI-TOF MS utilises a soft non-destructive ionisation method 
suitable for the analysis of polar molecules such as proteins and peptides (Figure 2.11) from 
bacteria and yeast[90]. This is an added advantage over a conventional ionisation approach 
that can identify smaller organic molecules (<1kDa). MALDI-TOF MS can be utilised 
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Figure 2.11 The first massspectrum of high molecular weight biomolecules[89]. 
Prior to sample analysis, the sample analyte is mixed in a matrix solution. The matrix 
solution is a weak acid with an aromatic ring structure and a carboxylic moiety. It absorbs at 
a wavelength of the laser resulting in a strong interaction between the matrix solution and the 
sample analyte. The matrix serves to protect the analyte from excessive energy and it 
enhances the ion formation of the analyte without reacting with it prior to laser 
irradiation[90]. Commonly used matrix solutions include 2.5-dihydroxy-benzoic acid 
(DHBA), sinnapinic acid (SA) and α-cyano-4 hydroxy-cinnamic acid (HCCA). During the 
sample preparation process, the sample (1ul) is spotted onto the MALDI-TOF ground steel 
target plate and then allowed to air dry. The spot is then overlaid with approximately 1ul of 
the matrix solution. The spots are then allowed to air dry and the plate is inserted into the 
MALDI-TOF ion source. In the ion source, the ions are emitted in a short laser pulse (brief 
burst). The irradiated becomes rapidly heated and vibrational. The accelerated ions attains a 
mass dependent velocity and moves from the ion source into the ‘drift’ or ‘field free’ tube 
where there different velocities (based on m/z) differentiate them as they move towards the 
detector (Figure 2.12)[90]. The laser energy absorbed by the matrix combined with the 
vibrational energy results in an explosion of the material in a plume just above the irradiated 
site. A high vacuum allows for desorption in the expanding plume of matrix compound 
‘carrying’ the analyte in the gas phase with minimal heating of the sample. In this manner 
intact bacterial proteins can be converted into the gas phase without any fragmentation or 
decomposition that is typical of conventional heat induced evaporation associated with 
traditional mass spectrometry systems. An acid base-equilibrium allows for protons from the 
carboxylic acid groups to be attracted to the proteins or polar analytes. 
In a linear TOF analyser, in the detector region, the mass-separated ions are counted giving 
rise to a signal for each mass-to-charge (m/z) that is equivalent to the number of ions 
present[90]. The TOF reflectron analyser reflects the ions back towards the source increasing 
the length of time. This approach has shown to increase the resolution power by a factor of 
2[90]. When it comes to the identification and characterization of bacteria, the TOF analyser 
is the more preferred mass analyser. The added advantage includes sensitivity, high mass 
range and speed. A high sensitivity is due to the ability of the analyser to detect all ions of 
‘like charges’ in a short time. Other analysers such as the ion trap analysers simply discard 
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ions with non-selected mass-to-charge values resulting in a reduced sensitivity. Ions up to and 
above 300kDa can be detected allowing for a high mass range. The TOF analyser is able to 










Figure 2.12 Accelerated ions with a mass dependent velocity travel from the ion source into the ‘drift’ or 
‘field free’ tube. There different velocities (based on m/z) differentiate them as they move towards the 
detector[90]. 
 
2.8.1 MALDI-TOF MS in Bacteriology 
 
Since the development of the MALDI-TOF MS in the 1980’s, it has been widely used for the 
analysis of proteins, nucleic acids, synthetic polymers and sugars[97]. Most of its 
applications were initially confined to areas of analytical chemistry, biotechnology and 
pharmaceuticals. Recently, a number of studies have demonstrated the potential of this 
application in the field of bacterial taxonomy [98,99]and for the analysis of macromolecules 
from biological origins[97]. When compared to previous mass spectrometry systems, 
MALDI-TOF MS has shown to have good resolution and mass accuracy for the detection of 
ions from macromolecules of biological origin in spite of the presence of small amounts of 
salts and other agents that can interfere with the mass spectrometric analysis[100].  
The MALDI-TOF MS approach is currently considered as an attractive tool for the rapid 
characterisation of bacteria and other microorganisms to the genus and species level. It has 
recently emerged as a method of choice for the rapid discrimination of microorganisms. It is 
used for the analyses of proteins of a bacterial cell thus allowing for reliable species-specific 
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identification. Microbial strain typing is based on the unique proteomic profile of a particular 
organism by assessing the exact size of important constituents such as peptides and proteins 
that characterise a bacterial species. The ‘soft’ ionisation method allows for the desorption of 
proteins from either whole cells or cellular extracts of bacteria, spores, viruses and fungi 
allowing for the generation of a proteomic profile of the microorganism of interest. A “Whole 
cell” analysis involves the analyses of cells that have not been chemically treated or 
mechanically disrupted for the removal or isolation of cellular components. This form of 
analysis allows for a rapid taxonomic classification of bacteria and its proven efficiency with 
reproducible spectral quality has made it an attractive tool in the field of diagnostic 
microbiology[90,101]. The pre analysis cellular extraction method is a more preferred 
method when it comes to the analysis of infectious microorganisms such as 
mycobacteria[102]. It renders the organism non-viable and safe for analysis by the MALDI-
TOF MS. The identification of microorganism particularly mycobacteria using mass spectra 
fingerprints is dependent on the reproducibility of the spectra. Therefore pre analysis sample 
preparation methods prior to MALDI analysis greatly influences the quality and 
reproducibility of the spectra. This study is one of few studies undertaken to optimize a 
sample preparation method for the discrimination of Mycobacteria using MALDI-TOF MS 
analysis. 
 
2.8.2 MALDI-TOF MS in Mycobacteriology 
The use of MALDI-TOF MS in the field of diagnostic mycobacteriology is relatively new. It 
has been used extensively for the identification of bacteria and fungi from whole cells and 
cellular extracts[103]. Hetticket al., 2004 conducted one of the first few studies aimed at 
looking at the identification of a number of unique biomarkers as targets for protein 
identification by MS/MS experiments[104]. 
Of relevance is work conducted by Pignoneet al. looking at 37 mycobacterial strains 
representing thirteen species and five subspecies that included the MTBCand the 
MACcomplex, as well as rapid- and slow-growing mycobacteria[1]. This method produced 
species-specific patterns for all but 1 of the 37 isolates and provided reliable differentiation at 
the strain level. This study has shown the potential of the MALDI-TOF MS as a rapid and 
reproducible method for the identification and characterization of Mycobacterium species 
using whole-cells. 
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To the best of our knowledge, very few studies have been conducted to discriminate 
mycobacteria to a strain level from cellular extracts using MALDI-TOF MS. Of note, the 
cellular extraction of proteins from pathogenic organisms is imperative so as to prevent 
disease transmission to the operator. Furthermore, the lack of a local mycobacterial database 
has been a limiting factor for mycobacterial identification, however; it can be supplemented 
by increasing the entries of mass spectra in the database. The current study is aimed at 
optimising a sample preparation protocol for the discrimination of mycobacteria to a species-
specific level using MALDI-TOF MS. 
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3.1 ABSTRACT 
Up until now proteomic profiling via matrix assisted laser desorption/ionisation time-of-flight 
mass spectrometry (MALDI-TOF MS) has been used for the identification of 
variousmicroorganisms (bacteria and yeast) to their genus and specie levels. For this purpose, 
either whole cells or samples containing proteins (cell surface proteins and ribosomal 
proteins)extracted from microbes with theethanol/formic acid (EFA) procedurewere used for 
MALDI-TOF MS analysis.However, unlike other bacteria, a major impediment exists in the 
efficient extraction of cellular proteins from mycobacteria due to the highly complex lipid 
structure of their cell wall envelopes. Therefore an EFA-based protein extraction method that 
uses micro-glass beads (EFAGB) to disrupt the cell envelope has also been suggested for 
biotyping of mycobacteria. The present study assesses the feasibility of using MALDI-TOF 
MS proteomic profiling as a rapid and precise technology to identify mycobacteria in 
Kwazulu-Natal, South Africa which is currently a global epicentre of mycobacterial-
associated diseases. However, the data from this locally-based study clearly shows that both 
the EFA and EFAGB protein extraction methods yielded less than satisfactory proteomic 
profiles for the purpose of accurate biotyping.As such a modifiedEFA protein extraction 
protocol that incorporates an initial cell envelope delipidation step was formulated and shown 
to produce mass spectra that were unique and highly reproducible. The spectrawere used to 
create an independent main spectral profile reference library (CMEFA-MSP) representing 
clinically relevant American Type Culture Collection (ATCC) mycobacterial strains. 
Interestingly, this proof of concept study clearly demonstrates that MALDI-TOF MS-based 
biotyping of mycobacteria using the CMEFA-MSP reference library correctly identified 11 
blind-coded strains sourced from an autonomous facility to the genus and species level with 
100% accuracy. 
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3.2 INTRODUCTION 
Microorganisms associated with the bacteria that cause tuberculosis (TB), leprosy and a 
variety of infections in humans are known as mycobacteria. Mycobacteria comprise of 
approximately 100 heterogeneous species of rapid and slow growing, acid-fast bacilli 
(AFB)[1,2] belonging to either the Mycobacterium tuberculosis complex (MTBC) or Non-
tuberculosis (NTM) family.Most members are harmless microbes, widely distributed in the 
environment and are normal inhabitants of a wide variety of environmental reservoirs, 
including natural and municipal water, soil, aerosols, animals and humans[3]. However there 
are a number of pathogenic species that infect humans and animals[4]. Over the past few 
decades the number of human infections caused by mycobacteria has increased[5]. 
Pulmonary infections, skin and soft tissue infections and disseminated disease are all 
responsible for significant morbidity in humans [6]. 
 
M. tuberculosis is a well-known human pathogen [7] belonging to the MTBC family. It 
remains the causative agent of the classically defined pulmonary tuberculosis in humans[8]. 
Other pathogens belonging to this genus include M. cannetii, M. africanum, M. bovis and M. 
microti[7]. A recent world-wide resurgence of M. tuberculosis has led to an increase of over 
95% tuberculosis cases and deaths occurring among adults in developing countries[9]. 
Tuberculosis (TB) itself continues to pose a major health risk to young and middle-aged 
adults and when associated with acquired immuno-deficiency syndrome (AIDS), it kills faster 
than any other disease. Globally, the current number of incident TB cases was estimated to be 
8.6 million in 2012, with 16.2 million prevalent cases of TB disease and 1.3 million deaths 
giving an overall case fatality rate of 23%[10]. Among these deaths, an estimated 170 000 
were due to multidrug-resistant TB (MDR-TB) [9]. South Africa is one of the twenty-two 
high-burden countries identified as having more than 80% of the new cases of TB worldwide 
and is reported to have the third highest TB burden in the world after India and China[11]. 
The HIV/AIDS epidemic has tremendously influenced the global burden of TB, with over 2 
million HIV-TB co-infected individuals living in South Africa[12]. KwaZulu-Natal is the 
leading province with high rates of TB as well as a high burden of multidrug-resistant (MDR-
TB) [13,14]. 
 
Although the incidence of classical tuberculosis has decreased in developed countries, the 
occurrence of NTM in pulmonary disease has increased [5]. Notably the HIV/AIDS epidemic 
has changed the epidemiology of NTM-related disease [14], leaving immunocompromised 
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individuals vulnerable to opportunistic infections caused by NTM [7]. NTM appears to be 
increasing worldwide with M. avium complex (MAC) being the leading cause of secondary 
infections in patients infected with HIV[7,12]. Strain types of M. avium isolates in AIDS 
patients were found to be identical to those isolates recovered from patients’ drinking water 
supplies [3]. Since M. avium and other NTM are resistant to chlorine and biocide, they are 
capable of biofilm formation and are able to persist in both natural and municipal water 
distribution systems [3]. Therefore water is likely the primary source of M. avium complex 
infection in humans with immunosuppression [3]. In first world countries MAC is a common 
causative agent of opportunistic infection in AIDS patients and represents about 65% of the 
NTM isolates. The other predominant cause of NTM infections includes M. fortuitum 
complex (19%) and M. kansasii (10%) with the remaining 10% being other mycobacterial 
species. Apart from MAC and other NTM associated infections, M. marinum is an emerging 
pathogen responsible for a variety of cutaneous infections in immunocompromised patients 
[7]. 
 
Conventional laboratory methods for the identification of NTM andMTBCorganisms rely on 
phenotypic characterization (growth rate, colony morphology, pigment production and 
staining techniques) and biochemical profiling. However, the main disadvantages associated 
with these methods are their extensive processing times (6-12 weeks to confirm a positive 
identification), which are considerably intensive in terms of both labour and cost [7]. 
Moreover and of particular concern is misidentification when processing large sample 
volume. According to Cook and co-researchers interspecies homogeneity, intraspecies 
variations and the existence of uncharacterized species often leads to phenotypic 
misidentification especially since taxonomic placement is solely dependent on technical 
personnel. Biochemical algorithms which usually include 15-20 species become too complex 
when attempting to include the hundreds of currently established species. As a result there is 
an inherent bias towards the identification of more familiar species of mycobacterium [15]. 
 
A drive to unequivocally discriminatemicrobes of both MTBC and NTM families and to 
speed up their presumptive identification as witnessed the development of a number of 
molecular biology-based strategies which include the hybridisation of PCR generated 
amplicons to specific probes and 16SrRNA gene sequencing. These methods have found 
favour in well-resourced privately- and government-owned pathology laboratories, as they 
aretechnically demanding and are dependent onexpensivelaboratory consumables and 
equipment.These methods are proving to be quiet effective for the detection of specific 
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Mycobacterium species within 3 weeks thus contributing positively to both patient care and 
prognosis. Unfortunately, only a limited number of mycobacterial species can be identified 
by these molecular biology-based assays[16]. 
 
Given the significant increase in mycobacterial-related infection rates and the limitations of 
the currently available identification methods described above, the development of a robust 
MTBC and NTM species differentiation method that is cost effective, simple, rapid and 
accurate is of paramount importance.A wide variety of prokaryotes (clinically and 
environmentally relevant Gram positive and negative bacteria) have been characterized using 
MALDI-TOF MS approach. Recent advances in mass spectrometry haveshown that 
comparative proteomic profiling can be employed in the identification of mycobacterial 
species[17,18]. Earlier studies by Hettick and coworkersusing MALDI-TOF MS analysis of 
whole-cellor acetonitrile/trifluoroacetic acid (ACN/TFA) extracted protein samples 
demonstrated that that both sample types were capable of resolving the identification of 6 
ATCC-typed mycobacterial strains.Thereafter, Pignoneand coworkersusedthe whole-cell 
sample preparation method and were able to clearly distinguish between 36 strains of the 37 
screened ATCC-typed mycobacteria. In a more recent study, undertaken by Saleeb and 
coworkers, a modified ethanol-formic acid (EFA) protein extractionprotocol using glass 
beads (EFAGB) was used to construct a mycobacterial mass spectral reference database 
containing 42 clinically relevant ATCC-typed strains. The database was then used albeit with 
varied success to biotype 104 mycobacterial clinical isolates. The above studies have 
useddifferent sample preparation methods for the proteomic profiling of mycobacteria using 
the MALDI-TOF MS.However, to date there seems to be no consensus on which sample 
preparation method is preferred in the discrimination of mycobacteria. In this regard, the 
present study assesses the feasibility of using MALDI-TOF MS proteomic profiling as a 
rapid and precise technology to identify mycobacteria in Kwazulu-Natal, South Africa which 
is currently a global epicentre of mycobacterial-associated diseases. 
 
In this proof-of-concept study we present the MALDI-TOF MS-derived proteomic profiling 
data on mycobacteria employing the EFA, EFAGB and a new organic solvent delipidation-
modified EFA (CMEFA)sample preparation protocol.The data from this comparative study 
seems to suggest that the newly developed CMEFA protocol is most effective in 
identification of clinically relevant ATCC-typed strains of mycobacteria representing 
members of the MTBC and NTM families that are prevalent in our locality. 
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3.3 MATERIALS AND METHODS 
 
3.3.1 Bacterial strains 
All mycobacterial species (Table 3.1)used in this study were procured from American Type 
Culture Collection (ATCC). The ATCC strains were purchased as a KWIK-STIK™ device 
(Microbiologics) consisting of lyophilised pellets.  
 
Table 3.1 Mycobacterial strains employed in this study. 
Mycobacterium Source 
M. abscessus ATCC 23040 ATCC 
M. avium ATCC 700736 ATCC 
M. bovis ATCC 19210 
ATCC 
M. fortuitum ATCC 23031 
ATCC 
M. gordonae ATCC 23409 
ATCC 
M. intracellulare ATCC 3950 
ATCC 
M. kansasii ATCC 12478 
ATCC 
M. marinum ATCC 927 
ATCC 
M. scrofulaceum ATCC 19981 
ATCC 
M. terrae ATCC 15755 
ATCC 
M. tuberculosis 25177 
ATCC 
 
3.3.2 Media Preparationand Cultivation of ATCC strains 
The mycobacterial ATCC strains were purchased as lyophilised pellets in a KWIK-STIK™ 
device (Microbiologics, USA). Mycobacterial pellets contained within the quick stick device 
was allowed to equilibrate to room and rehydrated according to manufacturer’s guidelines. 
The rehydration process was performed in a Level II Biosafety cabinet, with full personal 
protective equipment, including a N95 respiratory mask.A swab was heavily saturated with 
the fluid containing the mycobacterial organism and then transferred to a drug free 
Middelbrook 7H11 agar plate (Becton Dickinson). The Middelbrook 7H11 agar plate was 
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inoculated by gently rolling the swab over one-third of the plate. The culture plate was 
incubated at 37°C for four and twenty one days to cultivate fast (M. fortuitum) and slow 
growing (M. bovis, M. gordonae and M. tuberculosis) mycobacterial strains, respectively. 
Once confluent growth was obtained, a single loop-full was transferred into a 
MicroBankcryovial (Pro-Lab Diagnostics, Canada) and stored at -70°C as per manufacturer’s 
instruction.  
 
3.3.3 Standard ethanol-formic acid (EFA) sample preparation protocol 
A disposable 10 µl inoculating loop was used to obtain a single mycobacterial colony grown 
on Middelbrook 7H11 agar plate. The colony was suspended in 600 µl HPLC grade distilled 
water contained in a 1.5 ml screw cap “O” ring tube (Sarstedt, Germany). The tube 
containing the cell suspension was vortexed for approximately 60 s and heat inactivated at 
98οC for 30 min in a heating block. The heat inactivated cell suspension was then centrifuged 
at 13 000 x g for 5 min in a table top centrifuge with an aerosol–tight rotor. The supernatant 
was discarded and the pellet was re-suspended in 300 µl of HPLC grade distilled water and 
900 µl of absolute ethanol (HPLC grade). The cell suspension containing absolute ethanol 
was vortexed for 2 minat 13 000 x g and the supernatant was discarded using a pipette. An 
additional centrifugation step was performed to completely remove residual ethanol. After the 
pellet was air dried at room temperature (RT) for 5 min, depending on the volume of the 
pellet (ranging from 20-30 µl), 40-80µl of 70% formic acid was added and the tube was 
thoroughly vortexed for 30 s. An equivalent volume of absolute acetonitrile (HPLC grade) 
was added to the suspension and homogenized by vortexing for 10 s. The homogenized 
suspension was centrifuged for 2 min and the supernatant was transferred to a sterile 1.5 ml 
screw cap “O” ring tube. One microliter of the supernatant from each isolate was spotted onto 
MTP 384 ground steel target plate (Bruker Daltonics, Germany) and allowed to air-dry 
(Figure 3.1). One microliter of the Bruker Bacterial Test Standard (BTS) containing an 
extract of Escherichia coli DH5 alpha was spotted onto a separate spot for instrument 
calibration. The applied samples were air-dried and overlayed with a 1 µl aliquot of freshly 
prepared saturated matrix solution [10 mg of α-cyano-4-hydroxycinnamic acid (HCCA) 
dissolved in 1 ml of a solvent mixture containing 50% acetonitrile, 47.5% water and 2.5 % 
trifluoroacetic acid]. The samples containing matrix were dried for 5 min. The samples on the 
ground steel target plate were subjected to MALDI-TOFMS analysis. 
 










Figure 3.1 Application of samples to the MALDI-TOF MS ground steel plate. 
 
3.3.4 Ethanol-formic acid-glassbead (EFAGB) sample preparation protocol 
As suggested by Saleeb and coworkers, micro-glass beads was used to disrupt the cell 
envelope of mycobacteria so as to facilitate the release of cytoplasmic proteins[6]. The 
EFAGB mycobacterial sample preparation protocol for MALDI-TOF MS analysis was as 
follows: a 10µl disposable inoculating loop was used to obtain a single mycobacterial colony 
(ATCC typed strain) from a Middelbrook 7h11 agar plate. The colony was suspended in 600 
µl of HPLC grade distilled water contained in a 1.5 ml screw cap “O” ring tube (Sarstedt, 
Germany). The tube containing the cell suspension was vortexed for approximately 60 s and 
then heat inactivated at 98οC for 30 min in a heat block. The heat inactivated cell suspension 
was then centrifuged at 13 000 x g for 5 min in a table top centrifuge with an aerosol-tight 
rotor.The cell suspensions were vortexed for one min and heat inactivated at 103°C for 30 
min, whilst maintaining an internal tube temperature of 98°C. A micropestle was used to 
disperse mycobacterial cellular aggregates and the suspension was washed twice with HPLC 
grade distilled water (300 µl) and centrifuged at 13,000 rpm for 2 min. The supernatant was 
discarded and the pellet was re-suspended in 300 µl of HPLC grade distilled water followed 
by 900 µl of absolute ethanol (HPLC grade). The cell suspension containing absolute ethanol 
was vortexed for 2 minat 13 000 x g and the supernatant was discarded using a pipette. An 
additional centrifugation step was performed to completely remove all residual ethanol. After 
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the pellet was air dried at room temperature (RT) for 5 minand depending on the volume of 
the pellet (ranging from 20-30 µl), 40-80 µl of 70% formic acid was added followed by 100 
to 200µl of silica glass beads (0.1 mm diameter). The suspension was vortexed for 10 min 
followed by the addition of absolute acetonitrile (50 µl)and tubes were further vortexed for 10 
min. The sample was centrifuged for 2 min at 13 000 x g and the supernatant was utilized for 
MALDI-TOF MSanalysis. For analysis, 1 µl of the supernatant was spotted on a MTP 384 
ground steel target plate (Bruker Daltonics, Germany). The sample was allowed to air-dry 
and was subsequently coated with a 1 µl aliquot of freshly prepared saturated HCCAmatrix 
solution. The matrix coated samples were dried for 5 min before analysis. 
 
3.3.5 Chloroform-methanol ethanol-formic acid (CMEFA) sample preparation 
protocol  
The newly developed CMEFA protocol was evaluated for its effective delipidation of 
mycobacterial cells. Lipids and mycolic acids that constitute the mycobacterial cell envelope 
serve as barriers and hinder the protein extraction process resulting in fewer proteins 
available for definitive identification. The MALDI-TOF MS CMEFA sample preparation 
protocol for mycobacteria was as follows: a 10µl disposable inoculating loop was used to 
obtain a single mycobacterial colony (ATCC typed strain) from a Middelbrook 7h11 agar 
plate. The colony was suspended in 600 µl of HPLC grade distilled water contained in a 1.5 
ml screw cap “O” ring tube (Sarstedt, Germany). The tube containing the cell suspension was 
vortexed for approximately 60 s and then heat inactivated at 98οC for 30 min. The heat 
inactivated cell suspension was then centrifuged at 13 000 x g for 5 min in a table top 
centrifuge with an aerosol-tight rotor. The delipidation process of mycobacterial cells was 
initiated by the addition of 600 µl of a chloroform/methanol (1/1, v/v) solvent mixture. The 
cell suspensions were vigorously vortexed for 60 s, centrifuged at 13,000 x g for 5 min and 
the supernatants discarded. The delipidation treatment was repeated twice more so as to 
enhance the removal of lipids and mycolic acids. The supernatant was discarded and the 
pellet was re-suspended in 300 µl of HPLC grade distilled water followed by 900 µl of 
absolute ethanol (HPLC grade). The cell suspension was vortexed for 2 minat 13 000 x g and 
the supernatant was carefully removed. An additional centrifugation step was performed to 
completely remove all residual ethanol. The pellet was air dried at room temperature for 5 
min, depending on the volume of the pellet (ranging from 20-30 µl), 40-80 µl of 70% formic 
acid was added and the suspension was thoroughly vortexed for 30 s. Acetonitrile (50 µl) was 
added he suspension and tubes were vortexed for another 30 s. The samples were centrifuged 
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for 2 min at 13 000 x g. A 1µlaliquot of the supernatant was spotted on a MTP 384 ground 
steel target plate (Bruker Daltonics, Germany). The applied sample was air-dried and 
subsequently coated with 1 µlof freshly prepared saturated HCCA matrix solution. The 
extracted samples containing matrix were allowed to air-dry for 5 min before mass spectral 
analysis. 
 
3.3.6 MALDI-TOF MS instrumentation settings 
The spotted MTP 384 ground steel target plate was inserted into the tray of theAutoflex III 
smartbeam MALDI-TOF MS instrument (Bruker Daltonics, Germany) and processed using 
the Flex control software. Instrument parameters for ion source 1 and ion source 2 were set at 
20 kV and 18.57 kV respectively. The lens was set at 8.5kV and a pulsed ion extraction of 
250 ns was used. The protein molecules embedded in the matrix crystals were effectively 
desorbed and ionized by a smart beam laser pulse with a frequency of 20Hz and accelerated 
in a high voltage field. Different ions representing intact sample proteins proportional to their 
mass were detected after a time of- flight resulting in a high resolution mass spectrum of the 
sample. Spectra were acquired in a linear positive mode with a mass-to-charge (m/z) range of 
2to 20kDa. 
 
3.3.7 Mass spectral data analysis and library database creation 
Prior to sample analysis, the MALDI-TOF MS instrument was calibrated with the Bruker 
bacterial test standard (BTS) (Bruker Daltonics, Germany) with a mass range of 3.6 to 17 
kDa. The “MBT_FC.par” standard FlexControl method was selected for both analysis and 
internal calibration of BTS. Using the flex control method “MBT_FC.par”, calibration was 
performed automatically by adding up 6 times 40 laser shots from different positions of the 
BTS spot with the maximum deviation below ± 300 ppm as recommended by the 
manufacturer. Each mycobacterial strain was spotted at 6 positions on the MALDI target 
plate and measured four times per spot. Thus twenty four spectra were generated. Using 
replicate cultures, this was repeated on three separate occasions thereby generating 72 spectra 
per mycobacterial strain. The spectra fulfilled the specifications of Bruker Daltonics for 
construction of a new main spectral profile (MSP) reference library in that each spectrum 
must contain a minimum of 25 peaks with a resolution > 400, with a minimum of 20 of the 
peaks having a resolution > 500. 
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A main spectral profile (MSP) consisting of a minimum of 24 of the most reproducible 
spectra were created using the Biotyper 3.0 software individually for all eleven ATCC typed 
mycobacterial strains to generate a reference MSP database. An MSP is an average 
“spectrum” or “a reference peak list” which is created by a defined creation method from a 
number of pre-processed spectra acquired from a known or ATCC typed mycobacterialstrain. 
For quality assurance, all raw spectra used for MSP creation were processed according to a 
standardized protocol as advised by Bruker Daltonicsusing theFlexAnalysis 3 software 
program (Bruker Daltonics, Germany) and utilising the “MBT Process method” for the 
smoothing and baseline subtraction of raw spectra. The presence of flat-liners, outliers or 
single spectra with peaks differing from the other spectra was also interrogated using the 
FlexAnalysis 3 software program. The mass deviation within the spectra was set at not more 
than 500 ppm (mass window of 3 Dalton for a peak at 6 kDa) therefore any mass deviation 
above 3 Da, particularly for peaks at mass range between 6-7 kDa were eliminated. 
 
A list of the most significant peaks of a spectrum (m/z values with a given intensity) was 
created by performing functions within the FlexAnalysis such as smoothing, normalization, 
baseline subtraction and peak picking. Biotyper 3.0 software (Bruker Daltonics, Germany) 
was used to obtain themain spectral patterns (MSP’s) of mycobacteria processed in this study 
using the CMEFAextraction protocol. The newly generated MSP’s were used to create a new 
reference MSP libraryor database named CMEFA-MSP. Due to differences in sample 
preparation strategies, it must be noted that the CMEFA-MSP library is independent of the 
Bruker Daltonics main spectral profile database which currently stores reference spectra for 
more than 3740 microorganisms.Dendrogram analyses of MSP’s were processed with the 
Biotyper 3.0 software. 
 
3.3.8 Principle component analysis (PCA) 
In order to assess the complex relationships among the ATCC typed mycobacterial strains, a 
Principal component analysis (PCA) was generated using ClinProTools 2.2 software (Bruker 
Daltonics, Germany). Similarities or dissimilarities among mycobacterial strains were 
determined by the use of PCA plots. ATCC typed mycobacterial strains that cluster together 
are more similar than those that do not cluster. The PCA was managed by an external 
integrated MATLAB software tool integrated in ClinProTools to statistically evaluate 
MALDI-TOF mass spectra. 
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3.3.9 Biotyping of blind-coded strains using MALDI-TOF MS  
To access the accuracy and reliability of the CMEFA-based MALDI-TOF MS strategy in the 
identification of mycobacteria, eleven typed blind-coded strains were obtained from an 
independent institution (Medical Microbiology, NHLS, Inkosi Albert Luthuli Central 
Hospital).Samples for mass spectral analysis of the blind-coded strains were prepared using 
the CMEFA extraction method. Following acquisition of the mass spectra from blind-coded 
samples they were processed into their respective MSP’s. These were then best matched by 
Bruker Daltonics Biotyper 3 software to MSP’s in the newly created CMEFA-MSP reference 
library.Biotyping was performed from CMEFA-derived samples of three independent 
cultures of each blind-coded strain.Interpretation of the profile-matching process for 
theidentification of mycobacteria was made from log (score) values as shown in Table 3.2. 
 
Table 3.2 Interpretation ofBruker Daltonics identification score values [19]. 
 
Range Description Colour 
2.300 to 3.000 Highly probable species identification Green 
2.000 to 2.299 Secure genus and probable species identification Green 
1.700 to 1.999 Probable species identification Yellow 
0.000 to 1.699 No reliable Identification Red 
 
3.4 RESULTS 
In an attempt to minimize the health risk associated with the handling of pathogenically 
viable mycobacteria for MALDI-TOF MS analysis, all mycobacterial culture sampleswere 
heat inactivated prior to their extraction (EFA, CMEFA or EFAGB). The integrity of this 
inactivation measure was validated asno detectable mycobacterial growth was observed after 
6 weeks of incubation at 37°C on Middelbrook 7H11 agar plates.This inactivation procedure 
effectively rendered the mycobacteria non-viable and non-infectious significantly reducing 
the risk to the laboratory personnelindicating that the heat inactivation step had rendered the 
organism nonviable and was hereafter safe for work in an open laboratory [6]. 
The MALDI-TOF MS analysisof samples generated using the EFAprotocolyieldedmass 
spectral profiles with no discernible peaks and noresolution (results not shown, similar to 
Figure 3.2 C) that could not be employed in differentiatingmycobacterial species.In viewthis 
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major failing the EFA extraction method was not considered for further use. The EFAGB 
protocol which was modified by Saleeb and co-researchers to include mechanical disruption 
of mycobacterial cell envelopeglycopeptidolipids (GPL) with micro-glass beads [6], yielded 
protein mass spectral profiles that were characterised by drastically reduced peaknumbers 
with low intensities. This was especially evident for majority of the ATCC-typed 
mycobacterial strains (M. fortuitum, M. abscessus, M. gordonae and M. bovis)when 
compared to that of M. tuberculosis (Figure 3.2). The presence of smaller proteins with a 
mass/charge (m/z) ratio of <3.5 kDa was detected in most instances and little or no diagnostic 
ions were detected in in the higher mass/charge range. Given the limitation of the EFAGB 
method to yield samples that display consistent and abundant mass peaks throughout the 















Figure 3.2 Mass spectra of M. tuberculosis ATCC 25177 (A), M. bovis ATCC 19210 (B), M. gordonae 
ATCC 23409 (C), M. abscessus ATCC 23040 (D) and M. fortuitum ATCC 23031 (E) generated using the EFGB 
protein extraction method. The mass spectra with the exception (A) displayed very low numbers of mass peak 
signals with no peaks detected for (C). 
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In comparison to the EFA and EFAGB protocols, the delipidation step of mycobacterial cell 
walls incorporated into the newly developed CMEFA protocol yielded spectra with strong 
signals and abundant diagnostic ions across the entire mass/charge range (Figure 3.3).The 
enhanced mass spectral signatures were characterized by high peak intensities and a relative 
abundance of peaks with low signal-to-noise ratios. These spectra are reflective of 
samplescontaining higher protein content.Overall in comparison to spectra obtained using the 
EFA and EFAGB methods, a significantly increased number of diagnostic ions in the 














Figure 3.3 Mass spectra of M. tuberculosis ATCC 25177 (A), M. bovis ATCC 19210 (B), M. gordonae 
ATCC 23409 (C), M. abscessus ATCC 23040 (D) and M. fortuitum ATCC 23031 (E) samples obtained when 
using the CMEFA protein extraction protocol. The mass spectral signatures produced strong signals and 
adequate diagnostic ions in the mass/charge range of 2 to 10 kDa. 
To exclude for any interference from reagents of the CMEFA method on mass spectra, 
negative controls consisting of a culture-free chloroform/methanol (1:1, v/v) and distilled 
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water were included. The MALDI-TOF MS analyses of chloroform/methanol and 
distilledwater revealed no diagnostic ions (results not shown). In view of the above the 
CMEFA sample preparation protocol was deemed the method of choice for all further sample 
preparations. 
A set of mass spectral patterns for each ATCC-typed mycobacterial strain using the CMEFA 
protocol was further analysed using the MALDI- Biotyper 3.0 software to create their main 
spectral profiles (MSP). Using default analysis parameters as assigned by Biotypersoftware 
(distance measure, correlation; linkage, average), the differentiation and clustering of closely 
related mycobacteria wereascertained from a dendrogram (Figure 3.4). Notably, pathogenic 
members of MTBC (red) were differentiated and correctly clustered away from members 
ofNTMmycobacteria. Interestingly, mycobacteria of the M. avium-intracellulare 
complex(MAC) clustered separately indicating that the spectra of the species are more similar 
to one another than spectra of other mycobacterial species. A similar scenario prevails for 













Figure 3.4 Dendrogram created from hierarchical cluster analysis of the main spectral profiles (MSP) of 
mycobacteria using the CMEFA sample preparation protocol. 
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The results of the MALDI-TOF MS-based identification of blind-coded mycobacterial strains 
are presented in Table 3.3. These log score values were interpreted in accordance to 
stipulations by Bruker Daltonics (Table 3.2). InterestinglyCMEFA-prepared samples of 
theeleven blind-coded mycobacterial strains displayed of log score values ≥ 2.3 that placed 
them in the highestdescriptive category were identified correctly to the genus and species 
level. Of significance, the twoMTBC-related strains (M. tuberculosis andM. bovis)were 
unambiguously differentiated from the other nine NTM species. In this proof of concept 
study, MALDI-TOF MS-based biotyping correctly identified blind-coded strains to the genus 




Table 3.3 MALDI-TOF MS based identification of blind-coded ATCC-typed mycobacterial strains through 
pattern matching algorithms using Bruker Daltonics Biotyper 3.0 software. 
Sample Best matched strain Overall Score Values Identification 
1 M. fortuitum ATCC23031  2.44 ± 0.02 Yes 
2 M. kansasii ATCC 12478 2.40 ± 0.09 Yes 
3 M. scrofulaceum ATCC 19981 2.35 ± 0.10 Yes 
4 M. terrae ATCC 15755 2.39 ± 0.05 Yes 
5 M. abscessus ATCC 23040 2.42 ± 0.02 Yes 
6 M. marinum ATCC 927 2.42 ± 0.02 Yes 
7 M. tuberculosis ATCC 25177 2.44 ± 0.13 Yes 
8 M. bovis ATCC 19210 2.44 ± 0.07 Yes 
9 M. intracellulare ATCC 3950 2.40 ± 0.11 Yes 
10 M. gordonae ATCC 23409 2.41 ± 0.02 Yes 
11 M. avium ATCC 700736 2.40 ± 0.01 Yes 
Biotyping was performed from CMEFA-derived samples of three independent cultures of blind-coded strains. 
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To further characterisethe recently data-based main spectral profilesof CMEFA-extracted 
MALDI-TOF MS samples, the MSP’s of three ATCC typed mycobacterial strains were 
subjected to three dimensional principal component analyses (PCA).The mass spectra of M. 
tuberculosis, M. bovisand M. intracellulare were non-overlapping and reside in distinct 
spatial arrangementsto one another (Figure 3.5). Both MTBC membersM. tuberculosis and 










Figure 3.5 Three dimensional principal component analysis (PCA) derived from main spectral 
profiles (MSP’s) of M. tuberculosis ATCC 25177 (green), M. bovis ATCC 19210 (red) and M. 
intracellulare ATCC 3950 (blue). 
 
3.5 DISCUSSION 
For diagnostic purposes, current mycobacterial identification strategies to the species level 
primarily rely on  phenotypic analysis, complex biochemical tests, cultivation on specific 
growth media and genotype analysis [7].However, the main disadvantages that are associated 
with these techniques include extensive processing times (6-12 weeks to confirm a positive 
identification) and misidentification. Both factors severely hinder the control and 
management of diseases associated with mycobacteria, particularly tuberculosis.Apart from 
an increased patient mortality, interpersonal transmission of mycobacterial infections may 
increase. This scenario will also result in the prescription of inappropriate anti-tubercular 
treatment regimes.  
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In view of the above, innovative research has touted MALDI-TOF mass spectrometry as a 
promising candidate for the efficient strain typing of mycobacteria. Two types of sample 
preparation protocols for MALDI-TOF MS microbial biotyping are recommended by Bruker 
Daltonics, either the direct transfer whole cell method or an organic solvent protein extraction 
technique (EFA). To date, research studies have used both methods with no apparent 
preference [17,18]. Unlike other bacteria, mycobacteria are intrinsically resistant to 
conventional inactivation methods such as incubation in ethanol or in a saturated matrix 
solution. However, given the potential pathogenicity of mycobacteria, the use of cellular 
extracts instead of direct transfer whole cell analysis is a more preferred option. 
 
In a recent study, Saleeb and coworkers [6] modified the EFA method to include cellular 
disruption by glass beads (EFAGB) for MALDI-TOF MS-based biotyping of mycobacterial 
strains.It was hypothesized that mechanical agitation with zirconia-silica beads would break 
mycobacterial cell envelopes and release proteins needed for the accurate identification by 
MALDI-TOF MS [6]. The EFAGB protein extraction procedure was used to construct a 
mycobacterial mass spectral reference database (NIH database) containing 42 clinically 
relevant ATCC-typed strains. The reference database was used to differentiate 104 
mycobacterial clinical isolates and accurate identification was made with log score 
valuesranging from 1.8 to ≥ 2. 
 
In this proof of concept study, samples were extracted using the EFA and EFAGB methods 
from mycobacterial strains and their proteomic profiles were characterised using MALDI-
TOF MS. The mycobacteria included both rapid and slow growing strains representing 
eleven ATCC-typed strains from the two major mycobacterialfamilies: MBTC and NTM that 
are clinically relevant to high incidence mycobacterial infections in Kwazulu-Natal, South 
Africa. The data in this study clearly illustrates that EFA-prepared samples yieldedpoor mass 
spectral profiles with limited or no diagnostic ions. Surprisingly, the EFAGB processed 
samples in our setting also yielded mass spectra that were characterised by drastically 
reduced peak numbers with low intensities. As a result they were deemed inadequate for 
definitive mycobacterial strain identification. 
 
It has been established that microbe identification and discrimination is impossible when a 
limitednumber of diagnostic peak signals are obtained because strain differences are likely 
due to differences in the relative abundance of shared mass to charge (m/z) values of ions 
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[7,17]. In addition it has been previously suggested that precise bacterial taxonomic 
prediction based on proteomic profiles generated by MALDI-TOF MS analysis is dependent 
on the relative abundance of cellular proteins (cell surface proteins and ribosomal proteins) in 
cell sample extracts [20]. Thus it may be tentatively suggested that the EFA and EFAGB 
methods do not sufficiently disrupt the highly complex waxy cell envelopes of mycobacteria 
which are predominantly composed of mycolic acid containing glycopeptidolipids (GPL). 
The ability of to prevent the penetration of chemicals during the protein extraction process is 
supportive of this notion[21]. It has also been reported that these lipids bind to proteins and 
hinder theextraction and solubilisation of proteins that are critical to the generation of 
adequate positively charged ions necessary for MALDI-TOF MS analyses [22,23]. 
 
Given this backdrop, the present study developed a protein extraction protocol that 
wouldsupport unequivocal strain discrimination of the otherwise difficult to identify 
mycobacteria. In this regard, an enzymatic-basedmycobacterial cell wall disruption strategy 
was deemed unsustainable due to increased processing times and its cost intensive 
natureespecially when processing high sample volumes.Organic solvents such as phenol, 
chloroform and methanol have also been employed as mycobacterial cell wall disruption 
agents [1,24]. Bearing in-mind our region processes large sample sizes, the relatively low-
cost of organic solventsseemed an attractive alternative. Moreover andbased on the intrinsic 
character of lipids having a high affinity for nonpolar solvents it has been suggested that 
extraction with chloroform will increasethe fraction of membrane-associated proteins for 
MALDI-TOF MS analysis [25].In view of this, the present study modified the EFA protocol 
by incorporation a cell envelopedelipidation pre-treatment procedure with anequimixture 
containing chloroform and methanol. 
 
The data from this study clearly demonstrates that the newly developed organic solvent-based 
CMEFA protein extraction method is highly efficient in producing mycobacterial cellular 
protein samples for MALDI-TOF MSanalysis to generate high resolution MSP’s. In 
comparison to the EFAGB the CMEFA protocol is more cost-effective and simpler to 
perform as the chloroform-methanolequimixture facilitates disaggregation of mycobacterial 
cell clumps and thereby avoids use of cost-consuming sterile micropestles (∼1 $ per 
sample).In addition, the newly created independent CMEFA-MSP reference library 
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containing MSP’s of eleven ATCC-typed mycobacterial strains was used in the undisputable 
differentiation of blind-coded mycobacterial strains sourced from an independent research 
facility. Furthermore CMEFA-prepared samples of the eleven blind-coded mycobacterial 
strains displayed of log score values ≥ 2.3 which placed them in the highest descriptive 
category afforded by Bruker Daltonics thereby unambiguously identifying them to the genus 
and species level. 
 
To date, genomic sequencing platforms and many polymerase reaction assays that employ 
synonymous single nucleotide polymorphisms (sSNPS’s) are unable clearly discriminate 
betweenM. bovis and M. tuberculosisATCC-typed strains which share 99.5% similarity at the 
genetic level. As such these methods are currently restricted to resolvingthese organisms to 
theMTBC family [26]. A notable milestone of this study is that M. tuberculosis and M. bovis 
strains were individually resolvedbased on their unique CMEFA-derived cellular proteomic 
profiles.This lends credence to the proposal that genomic differences between M. bovis and 
M. tuberculosis most probably could be distinguished at the protein level[26].In a similar 
scenario, the data clearly demonstrates the ability of the CMEFA protein extraction strategy 
to facilitate species level discriminationof NTM microbes from each other and from 
individual MTBC organisms. Although the data presented herein strongly suggests that 
CMEFA-based MALDI-TOF MS analysis should be the most preferred method for 
mycobacterial biotyping its true potential remains to be assessed with the creation of a 
complete mycobacterial strain MSP reference library to screen and identify clinical 
mycobacterial isolates. In addition CMEFA-based MALDI-TOF MS biotyping should be 
validated using a multi-laboratory approach. 
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4.1 ABSTRACT 
The identification of mycobacteria to the genus and species level in most diagnostic 
pathology laboratoriesprimarily relies on phenotypic and biochemical characterization 
methods. More recently, commercially available molecular biology-based genotyping 
methodsare being used for this purpose. However, these well-established protocols are labour 
intensive, require considerable technical expertise and sometimes yield unacceptable 
misidentifications. Matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS) has been reported as areliable, economicaland highly 
efficientmethod for both bacterial and yeast strain identification. To date, it has been used to 
a limited extent to discriminate the mycobacteria which are notoriously challenging to type to 
the species level. In this study, anovel chloroform-methanol-ethanol-formic acid (CMEFA) 
sample preparation protocol is used for the extraction of cellular proteins from clinical 
mycobacterial isolates for MALDI-TOF MS analysis. The data of this study, 
clearlydemonstrates that CMEFA-prepared samples of clinical isolates gave highly 
reproducible and distinctive mass spectral profiles. A main spectral profile (MSP) reference 
database representing ATCC-typed mycobacteria (CMEFA-MSP) was employed to 
identify39 blind-coded clinical mycobacterial isolates. Importantly all CMEFA-derived 
samples of the 39clinical isolates displayed log score values of ≥2.3 and were correctly 
identified to the species level. This strongly suggests that MALDI-TOF MS when used in 
conjunction with the CMEFA sample preparation protocol has potential as a simpleand cost-
effective alternative for the unambiguousidentification of clinically important mycobacteria. 
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4.2 INTRODUCTION 
Members of the Mycobacteriaceae family are responsible for a wide range of diseases in 
humans and lower animals[1]. In humans, these diseases range from superficial infections of 
the skin caused by M. marinum[2-4], to pulmonary disease caused by both MTBand NTM. 
Tuberculosis (TB) still remains a disease of great antiquity and was one of the first diseases 
for which the World Health Organization (WHO) declared a global public health emergency 
in 1993[3]. Presently, it is estimated that one-third of the world’s population is infected with 
MTB[5]. An estimated 8 to 9 million new cases occur each year, with 2 to 3 million 
deaths[5,6]. Pulmonary TB is characterized by prolonged cough, hemoptysis, chest pain and 
dyspnea whilst symptoms of systemic and disseminated disease include fever, malaise, 
weight loss, weakness and night sweats[7-9].  
Awidespread occurrence of NTM-related diseasesdueto Mycobacterium avium Complex 
(MAC), M. kansasii and other NTM’shave been observed in the period of HIV-
AIDS[3,10,11]. During this period, a salient observation was seenin patients who had CD4 
counts of less than 50/ml presenting withbloodstream associated MAC infections. Of note, 
NTM’s particularly M.avium, M.kansasii, and M.intracellulareproduce pulmonary disease in 
humans that may be indistinguishable from that caused by the members of the MTBC 
(M.tuberculosis and M.bovis)[3]. There is a significant difference in the treatment of NTM 
relatedpulmonary infections and tuberculosis caused by MTB. As a result, a species-level 
identification of mycobacteriais necessary for the selection of appropriate antimicrobial 
therapy[12,13]. 
A microscopic evaluation of an auramine stain, although widely used in low-income 
countries for the diagnosis of TB, isunable to confirm the presence of viable 
mycobacteria[14]. An over-diagnosis of a treatment failure may possibly be the final outcome 
after performing a sputum smear microscopic on a sputum sample received from a patient on 
treatment[14]. Routinely employed laboratory methods for the species identification of 
mycobacteria such as growth rate, biochemical tests, analysis of antibiotic resistance patterns 
and HPLC (high pressure liquid chromatography) analysis of fatty acid constituents of the 
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bacterial cell wall are time-consuming, requiring as long as 6-12 weeks to confirm a positive 
identification[3,15,16]. According to Buchan et al., HPLC is insufficient to accurately 
differentiate between closely related species such as M. chelonae/M. abscessus, M. avium/M. 
intracellulare, and species within the M. mucogenicum group, which may be important to 
patient care decisions [12]. In addition to the above, mycobacterial isolates from patients with 
chronic infections often lose their characteristic phenotypes, thus hindering the performance 
of several conventional diagnostic methods[3]. 
In most pathology TB laboratories in South Africa, commercially available Genotypic PCR-
based identification assays coupled with reverse line hybridization are widely used for 
thedetection ofpolymorphisms within the 16S or 23S rRNA. These methods have been 
widely utilised for the species-specific identification and differentiation of more than 30 
clinically relevant mycobacterial species[13,17] and when coupled with other diagnostic 
modalities have been shown to greatly reduce the diagnostic turnaround (TAT) to a week. 
However limitations such as misidentification, inability to discriminate closely related 
members of the MTBC as well as the emergence of new species, limits these diagnostic 
assays to only detecting a few mycobacteria[13,18,19].A more expensive approach involving 
sequencing of the 16S rRNA has been widely accepted as the reference method for species 
identification[20]. However, the analysis of sequence data can be quite cumbersome and the 
retrieval of valid identification results requires the use of a comprehensive quality-controlled 
database[21]. As a result many researchers are looking for a cost effective, rapid and 
reproducible method to differentiate between a wider range of mycobacterial species. 
Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF 
MS) has been recently recognized for its ability to identify bacteria to a species level through 
the analysis of the protein composition of a bacterial cell [17,22]. The principle of MALDI-
TOF MS for the identification of bacterial species is based on the ability of the assay to 
measure the exact sizes of peptides and proteins through the generation of a unique mass 
spectral profile[17,23]. Various factors including a low reproducibility of the results, 
variations in the sample preparation protocol and a limited availability of reference data have 
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made it impossible to routinely utilize the application of MALDI-TOF MS for the speciation 
of mycobacteria in a clinical laboratory[21]. Furthermore, the applications of MALDI-TOF 
MS for the discrimination of clinically relevant mycobacteriausing a reference library 
database have been documented in a limited number of studies[12,19,21,24,25]. Currently 
there is no preference on which sample preparation method to use since whole-cell deposits, 
cell lysates, or crude bacterial extracts have been previously recommended. Given the 
pathogenic nature of mycobacteria, cellular extraction has been a more preferred method 
option as opposed to whole cell deposits since this method minimises contact with the 
infectious organism. Thus far and to the best of our knowledge a studydemonstrating the 
application of MALDI-TOF MS for the identification of clinically relevant mycobacterial 
isolates in KwaZulu-Natal, South Africa has not yet been conducted. Therefore the present 
study is the first of the relatively few studies presented to evaluate a newly developed 
chloroform-methanol-ethanol-formic acid (CMEFA) cellular extraction protocol for the 
identification and differentiation of clinically significant mycobacterial isolates using 
MALDI-TOF MS. The MALDI-TOF MS bioinformatics and statistical algorithms such as 
pattern-matching algorithm, cluster analysis, and principal component analysis (PCA)were 
also evaluated during the identification and discrimination of clinical mycobacterial 
isolates.The reference spectral database library (CMEFA-MSP, Chapter 3) waschallenged 
using blind-coded clinically relevant mycobacterial isolates sourced from an independent 
facility. 
 
4.3 MATERIALS AND METHODS 
4.3.1  Mycobacterial strains and clinical isolates 
Eight different mycobacterial species consisting of American Type Culture Collection 
(ATCC) strains and clinical isolates were used in this study (Table 4.1). The ATCC strains 
were purchased as a KWIK-STIK™ device (Microbiologics,USA) consisting of lyophilised 
pellets. The clinical isolates were well characterised using the Genotype CM (Common 
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Mycobacteria), AS (Additional Species) and MTBC (Mycobacterium tuberculosis Complex) 
assays (Hain-Lifescience, Nehren Germany). 
Table 4.1 Mycobacterial ATCC-typed strains and clinical isolates employed in this study. 
Mycobacteria No. of Clinical Isolates Source 
M. abscessus ATCC 23040  ATCC 
M. abscessus 8 Clinical isolates 
M. avium 4 Clinical isolates 
M. bovis  ATCC 
M. fortuitumATCC 23031  ATCC 
M. fortuitum 15 Clinical isolates 
M. gordonaeATCC 23409  ATCC 
M. gordonae 4 Clinical isolates 
M. intracellulareATCC 3950  ATCC 
M. intracellulare 3 Clinical isolates 
M. marinum ATCC 927  ATCC 
M. marinum 2 Clinical isolates 
M. scrofulaceumATCC 19981  ATCC 
M. scrofulaceum 1 Clinical isolates 
M. tuberculosis ATCC 25177  ATCC 
M. tuberculosis 2 Clinical isolate 
 
 
4.3.2 Media and Culture Preparation of ATCC strains 
The mycobacterial ATCC strains were purchased as lyophilised pellets in the form of a 
KWIK-STIK™ (Microbiologics,USA) device packaged within a pouch. Mycobacterial 
pellets contained within the quick stick device was allowed to equilibrate to room and 
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rehydrated according to manufacturer’s guidelines. The rehydration process was performed in 
a Level II Biosafety cabinet, with full personal protective equipment, including a N95 
respiratory mask. A swab was heavily saturated with the fluid containing the mycobacterial 
organism and then transferred to a drug free Middelbrook 7H11 agar plate (Becton 
Dickinson,USA).The Middelbrook 7H11 agar plate was inoculated by gently rolling the swab 
over one-third of the plate. The culture plate was incubated at 37°C for four and twenty one 
days to cultivate fast (M. fortuitum) and slow growing (M. gordonaeand M. tuberculosis) 
mycobacterial strains respectively. Once confluent growth was obtained, a single loop-full 
was transferred into a MicroBankcryovial (Pro-Lab Diagnostics, Canada) and stored at -70°C 
as per manufacturer’s instruction.  
 
4.3.3 Acquisition andGenotypic-based Identification of Clinical Isolates 
The following aspects relating to the collection, cultivation and identification of the 39 
clinical isolates of mycobacteria used in this study were performed by the NHLS (National 
Health Laboratory Service) TB reference pathology laboratory based at Inkosi Albert Luthuli 
Central Hospital (IALCH). The isolates are presented in Table 4.1 and it must be highlighted 
that this screening process did not source and identify clinical isolates representing M. bovis, 
M. kansasii and M. terrae. This is indeed not surprising due to the extremely infrequent 
incidence of M. bovis,M.kansasiiand M. terraerelated mycobacteriosis in the Durban 
metropolis of KwaZulu-Natal. 
 
4.3.3.1 Collection and culturing of clinical isolates of mycobacteria 
A large number of sputum samples representing putative clinical mycobacterial infections 
were collected from different regional hospitals of Durban, South Africa. Sputum samples (1 
ml) were decontaminated with an equal volume N-acetyl-L-cysteine-sodium hydroxide 
(NALC-NaOH). All putative mycobacterial specimen manipulations were performed in a 
biological safety cabinet class-II equipped with high-efficiency particulate air filters (HEPA). 
The samples were allowed to stand at room temperature for 15-20 min. Sodium phosphate 
buffer (pH 6.8; 48ml) was added to samples and centrifuged at 3,000 x g for 15 min. The 
sediment was retained with approximately 3 ml of supernatant. The samples were vigorously 
vortexed and 100 µl of the suspension was subjected to auramine-O staining to confirm the 
presence of acid-fast bacilli [26]. 
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Mycobacterial growth indicator tubes (MGIT) supplemented with a BBL™ MGIT™ OADC 
enrichment and BBL™ MGIT™ PANTA™ antibiotic mixture (Becton Dickinson, USA) 
were inoculated with decontaminated sputum sediments and incubated in the Bactec 960 
mycobacterial detection system (Becton Dickinson, USA). Only MGIT-positive cultures 
were further assessed for the presence of an acid fast bacilli (AFB) using a ZiehlNeelsen 
(ZN) stain. All AFB positive MGIT cultures were then sub-cultured onto drug free solid 
Middelbrook 7H11 agar and incubated at 37°C. Genotypic-based identification of isolates 
was performed on cultures that displayed confluent growth between 4 and 21 days. 
 
4.3.3.2 Genotypic-based screening of clinical isolates of mycobacteria 
Speciation of isolates was performed according to manufacturer’s instructions using the 
Genotype CM (Common Mycobacteria), AS (Additional Species) and MTBC assays (Hain-
Lifescience GmbH, Nehren Germany). This technique uses DNA strip technology based on 
the reverse hybridization of PCR products to their complementary probes and targets the 23S 
rRNA gene region for the simultaneous detection and identification of mycobacteria. 
Subspecies of the M.tuberculosis complex (MTBC) were easily discriminated using the 
primer nucleotide mix (PNM) provided with the Genotype MTBC assay. The PNM mix 
targets the 23S ribosomal DNA fragment, detectsgyrBDNA sequence polymorphisms and the 
RD1 deletion of M.bovis BCG for an accurate speciation[17]. The protocol consisted of DNA 
extraction, PCR amplification, reverse hybridization of the amplified PCR products to 
species-specific oligonucleotide probes (probe sequences immobilized on nitrocellulose 
strips) followed by chemical detection. 
 
4.3.3.2.1 Isolation of genomic DNA 
A single colony of culture isolate was harvested using a disposable 10 µl inoculating loop on 
Middlebrook 7H11 agar plate and suspended in 300µl of molecular grade distilled water 
contained within a 1.5 ml screw cap “O” ring tube. The tubes were vortexed for 
approximately 10 s and the mycobacterial cells were pelleted by centrifuging at 10 800 x g 
for 15 min in a table-top centrifuge with an aerosol-tight rotor. The supernatant was discarded 
and the pellet resuspended in 100µl of molecular grade distilled water. The suspension was 
incubated for 30 min at 98°C in a heat block to allow for heat inactivation and cell lysis. This 
process was followed by sonication in an ultrasonic water bath for 15 min at room 
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temperature (RT). After a centrifugation at 10800 x g for 5 min, free DNA present in the 
supernatant was used as a DNA template (5µl) for PCR amplification. 
4.3.3.2.2 PCR amplification 
DNA was amplified using species specific optimized primers provided with the Genotype 
CM, AS and MTBC assay. The PCR amplification was performed in a 50µl reaction mixture 
consisting of 5µl DNA template, 35µl primer- nucleotide mix (PNM), 5µl PCR buffer, 2µl of 
a 2.5mM MgCl2, 0.2µl of a 1.25 U hot startTaq DNA Polymerase (Qiagen, Hilden, Germany) 
and 3µl distilled water. Amplification was performed in an ABI 2700 thermocylcer (Applied 
Biosystems, USA) under the following PCR cycling conditions: denaturation at 95°C for 15 
min; 10 cycles of denaturation at 95°C for 30s and elongation at 58°C for 120s; an additional 
20 cycles of denaturation at 95°C for 25s; annealing at 53°C for 40s and elongation at 70°C 
for 40s and a final extension of 70°C for 8min. 
 
4.3.3.3 DNA Hybridization 
The hybridization of PCR-generated fragments to probes was performed in a semi-automated 
washing and shaking device(Twincubator, Hain-Lifesciences, Nehren, Germany). 
Hybridization was initiated by denaturing 20µlof the amplified double stranded DNAinto 
single strands using 20µl of denaturing (DEN) solution. Single stranded DNA was hybridized 
to membrane bound probes for 30min at 45°C using a pre-warmed hybridisation solution. All 
steps were carried out in a plastic hybridisation plate with the DNA samples treated in 
separate wells. The unbound amplicons were removed using a stringent wash solution. 
Several rinse solutions were used for washing off amplicons at 25°C. Hybridised amplicons 
containing biotin were chromogenically visualised using streptavidin conjugated with an 
alkaline phosphatase. A substrate buffer was also added to generate the formation of a 
colourful band. At least two wash steps were performed to stop the reaction, allowing for the 
strips to be air dried and interpreted. Once the test strips were attached to a Genotype 
template, the development of a conjugate, universal and genus control bands were carefully 
assessed for each isolate. Reactions with banding patterns whose intensities were as strong as 
or stronger than the universal control line were interpreted. Specific banding patterns 
composed of clear cut hybridisation and colorimetric staining signals on a nitrocellulose 
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membrane strip are shown in Figure 4.1. Strain identification was performed according to the 
manufacturer’s guideline(Figure 4.2 and 4.3) which stipulatesthetheoretical banding patterns 
of different mycobacterial species. 
 
Figure 4.1 Genotype CM assay (Strips A, B and C). M.fortuitum (StripA, bands 7 and 14), M.avium (StripB, 
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Figure 4.3 Interpretation chart for the Genotype CM (A) and AS (B) assays. Bands from top to bottom 
are as follows: 1, conjugate control (CC); 2, universal control (UC); 3, genus control (GC); 4 to 17, species-
specific probes for the identification of individual and combined mycobacterial species. Gram-positive bacteria 
with a high G+C content in their DNA are indicated by the superscript “a”. The filled boxes represent staining, 
striped boxes represent facultative staining; grey boxes represent facultative weak staining and blank boxes 
represent no staining (Hain-LifeSciences, Nehren, Germany). 
4.3.4 MALDI-TOF MS Proteomic Profiling of Clinical Isolates 
 
4.3.4.1 Chloroform-methanol ethanol-formic acid (CMEFA) extraction protocol  
The newly developed CMEFA protocol was evaluated for its effective delipidation of 
mycobacterial cells. Lipids and mycolic acids that constitute the mycobacterial cell envelope 
serve as barriers and hinder the protein extraction process resulting in fewer proteins being 
available for accurate identification by MALDI- TOF MS. The CMEFA sample preparation 
protocol for mycobacteria was as follows: a 10µl disposable inoculating loop was used to 
obtain a single mycobacterial colony from a Middelbrook 7H11 agar plate containing 
growths of either an ATCC mycobacterial strain or a clinical isolate. The colony was 
suspended in 600 µl of HPLC grade distilled water contained in a 1.5 ml screw cap “O” ring 
tube (Sarstedt, Germany). The tube containing the cell suspension was vortexed for 
approximately 60 s and then heat inactivated at 98οC for 30 min. The heat inactivated cell 
suspension was then centrifuged at 13 000 x g for 5 min in a table top centrifuge with an 
aerosol-tight. The delipidation process of mycobacterial cells was initiated by the addition of 
600 µl of a chloroform/methanol (1/1, v/v) solvent mixture. The cell suspensions were 
vigorously vortexed for 60 s, centrifuged at 13,000 x g for 5 min and the supernatants 
discarded. The delipidation treatment was repeated twice more so as to enhance the removal 
of lipids and mycolic acids. The supernatant was discarded and the pellet was re-suspended in 
300 µl of HPLC grade distilled water followed by 900 µl of absolute ethanol (HPLC grade). 
The cell suspension was vortexed for 2 minat 13 000 x g and the supernatant was carefully 
removed. An additional centrifugation step was performed to completely remove all residual 
ethanol. The pellet was air dried at room temperature for 5 min, depending on the volume of 
the pellet (ranging from 20-30 µl), 40-80 µl of 70% formic acid was added and the 
suspension was thoroughly vortexed for 30 s. Acetonitrile (50 µl) was added to the 
suspension and tubes were vortexed for another 30 s. The samples were centrifuged for 2 min 
at 13 000 x g. A 1µl aliquot of the supernatant was spotted on a MTP 384 ground steel target 
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plate (Bruker Daltonics, Germany). The applied sample was air-dried and subsequently 
coated with 1 µl of freshly prepared saturated HCCA matrix solution. The extracted samples 
containing matrix were allowed to air-dry for 5 min before mass spectral analysis. 
4.3.4.2 MALDI-TOF MS instrumentation 
The spotted MTP 384 ground steel target plate was inserted into the tray of theAutoflex III 
smartbeam MALDI-TOF MS instrument (Bruker Daltonics, Germany) and processed using 
the Flex control software. Instrument parameters for ion source 1 and ion source 2 were set at 
20 kV and 18.57 kV respectively. The lens was set at 8.5kV and a pulsed ion extraction of 
250 ns was used. The protein molecules embedded in the matrix crystals were effectively 
desorbed and ionized by a smart beam laser pulse with a frequency of 20Hz and accelerated 
in a high voltage field. Different ions representing intact sample proteins proportional to their 
mass were detected after a time of-flight resulting in a high resolution mass spectrum of the 
sample. Spectra were acquired in a linear positive mode with a mass-to-charge (m/z) range of 
2to 20 kDa. 
 
4.3.4.3 Acquisition of MALDI-TOF MS data 
Prior to sample analysis, the MALDI-TOF MS instrument was calibrated with the Bruker 
bacterial test standard (BTS) (Bruker Daltonics, Germany) with a mass range of 3.6 to 17 
kDa. The “MBT_FC.par” standard FlexControl method was selected for both analysis and 
internal calibration of BTS. Using the flex control method “MBT_FC.par”, calibration was 
performed automatically by adding up 6 times 40 laser shots from different positions of the 
BTS spot with the maximum deviation below ± 300 ppm as recommended by the 
manufacturer. Each mycobacterial ATCC-typed strainor clinical isolate was spotted at 6 
positions on the MALDI target plate and measured four times per spot. Thus twenty four 
spectra weregenerated using replicate cultures; this was repeated on three separate occasions 
thereby generating 72 spectra per mycobacterial sample.The spectra fulfilled the 
specifications of Bruker Daltonics for construction of a main spectral profile (MSP) in that 
each spectrum must contain a minimum of 25 peaks with a resolution > 400, with a minimum 
of 20 of the peaks having a resolution > 500.A main spectral profile (MSP) consisting of a 
minimum of 24 of the most reproducible spectra were individuallycreated using the Biotyper 
3.0 software for all mycobacterial samples. 
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For quality assurance, all raw spectra used for MSP creation were processed according to a 
standardized protocol as advised by Bruker Daltonicsusing theFlexAnalysis 3 software 
program (Bruker Daltonics, Germany) and utilising the “MBT Process method” for the 
smoothing and baseline subtraction of raw spectra. The presence of flat-liners, outliers or 
single spectra with peaks differing from the other spectra was also interrogated using the 
FlexAnalysis 3 software program. The mass deviation within the spectra was set at not more 
than 500 ppm (mass window of 3 Dalton for a peak at 6 kDa) therefore any mass deviation 
above 3 Da, particularly for peaks at mass range between 6-7 kDa were eliminated. A list of 
the most significant peaks of a spectrum (m/z values with a given intensity) was created by 
performing functions within the FlexAnalysis such as smoothing, normalization, baseline 
subtraction and peak picking. Biotyper 3.0 software (Bruker Daltonics, Germany) was used 
to obtain themain spectral patterns (MSP’s) of mycobacteria processed in this study using the 
CMEFAextraction protocol. 
 
4.3.4.4 Principle component analysis (PCA) 
Principle component analysis (PCA) was employed to statistically evaluate MALDI-TOF 
mass spectra. PCA is a broadly used mathematical technique for reducing the dimensionality 
of multivariate data whilst preserving most of the variance. PCA was performed using 
ClinProTools software 2.2 (Bruker Daltonics, Germany). The PCA is managed by an external 
MATLAB software tool, which is integrated in ClinProTools. Prior to PCA analysis spectra 
were processedinto their MSP’s as described above. Complex relationships between samples 
of mycobacterial isolates were explored and illustrated with the use of a PCA plot. This 
model provides insights into similarities or dissimilarities between samplesof mycobacterial 
isolates. For example samples that cluster closer together are more similar than samples that 
are further apart. 
 
4.3.4.5 Biotyping of blind-coded isolates using MALDI-TOF MS 
To access the accuracy and reliability of the CMEFA-based MALDI-TOF MS strategy in the 
identification of mycobacteria, 39blind-coded mycobacterial isolates were obtained from an 
independent institution (Medical Microbiology, NHLS, Inkosi Albert Luthuli Central 
Hospital).Samples for mass spectral analysis of the blind-coded isolates were prepared using 
the CMEFA extraction method. Following acquisition of the mass spectra from blind-coded 
samples they were processed into their respective MSP’s. An MSP was then identified or 
speciated by Bruker Daltonics Biotyper 3 software by comparison to those contained within 
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the CMEFA-MSP reference library of ATCC-typed mycobacterial strains (Chapter 
3).Biotyping was performed from CMEFA-derived samples of three independent cultures of 
each blind-coded isolate. The results from the profile-matching process were expressed as log 
(score) values and ranged from 0 to 3 as shown in Table 4.2. 
Table 4.2 Interpretation of Bruker Daltonics identification score values [27]. 
Range Description Colour 
2.300 to 3.000 Highly probable species identification Green 
2.000 to 2.299 Secure genus and probable species identification Green 
1.700 to 1.999 Probable species identification Yellow 




The mass spectral fingerprints generated from CMEFA extracted proteinsamples of clinical 
mycobacterial isolates were defined by strong signals and abundant diagnostic ions across the 
entire mass/charge range (Figure 4.5). The mass spectral signatures of individual isolates 
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Figure 4.4 Mass spectra of clinical mycobacterialisolates generated with MALDI-TOF MS using CMEFA 
protein extraction method. (A) M. abscessus, (B) M. fortuitum and (C) M. marinum. 
To further characterise the main spectral profiles of CMEFA-extracted samples, the MSP’s of 
five clinical isolates were subjected to three dimensional principal component analyses 
(PCA) [Figure 4.5]. Replicate spectra from closely related species formed discrete clusters 
with little variation.Of importance, the MSP’s of MTB and NTM isolates reside in distinct 
spatial arrangementsto one another that were non-overlapping (Figure 4.5). The MTB isolate 
clustered away from the clinically significant NTM isolates. Of relevance is that M. avium 
and M. intracellulare, although closely related at a biological level, clustered on different 




Figure 4.5 Three dimensional principal component analysis (PCA) derived from main spectral patterns 
ofmycobacterial clinical isolates.M. tuberculosis(red), M. marinum(blue), M. intracellulare(green), M. avium 
(yellow) and M. scrofulaceum (black). 
 
 
The results of the MALDI-TOF MS-based identification of blind-coded clinical 
mycobacterial isolates are presented in Table 4.3. Interestingly all of the39blind-coded 
mycobacterial isolateswhen best matched by Bruker Daltonics Biotyper 3 software to MSP’s 
of the CMEFA-MSP reference librarydisplayedlog score values ≥ 2.3 and were identified 
Chapter 4  Research Results II 
84 
correctly to the genus and species level (Table 4.3). TheM. tuberculosisisolate was 
unambiguously differentiated from theNTM isolates. In this study, MALDI-TOF MS-based 
biotyping correctly identified blind-coded mycobacterial isolates to the genus and species 
level with 100% accuracy. 
Table 4.3 MALDI-TOF MS-based identification of blind-coded mycobacterial isolates. 
Sample Number of isolates Best match Score Values Identification 
1a to 1c 3 M. intracellulare > 2.3 Yes 
2a to 2d 4 M. avium ≥ 2.3 Yes 
3a to 3o 15 M. fortuitum > 2.3 Yes 
4a to 4d 4 M. gordonae ≥ 2.3 Yes 
5a & 5b 2 M. marinum > 2.3 Yes 
6 1 M. scrofulaceum ≥ 2.3 Yes 
7a to 7h 8 M. abscessus > 2.3 Yes 
8a & 8b 2 M. tuberculosis > 2.3 Yes 
 
 
A set of mass CMEFA -derived spectral patterns for each ATCC-typed mycobacterial strain 
and clinical isolate were further analysed using the Biotyper 3.0 software to create a main 
spectral profile (MSP).A dendrogram was created using default analysis parameters as 
assigned by Biotyper software (distance measure, correlation; linkage, average) to access the 
differentiation and clustering of these mycobacteria (Figure 4.6). Notably, M. tuberculosis 
and M. bovis organisms from MTBC wereclearly differentiated from each other. In addition 
the MTBC-related organisms (ATCC and clinical isolates) correctly clustered away from 
NTM-related mycobacteria. 
 
The MSP’s of NTM-related mycobacteria fell into two major cladeswith M. 
avium,M.intracellulare, M. scrofulaceum,M. marinumandM. gordonae in one clad whilst the 
other contained M. fortuitum and M. abscessus. It was also noted that each of the NTM 
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family members formed individually discreet clusters. The latter phylogeny is indicative of 
high levels of spectral similarities in terms ofthe location and intensity of diagnostic ions.Due 
to negligible differences in distance, the proteomic profiles of the 15 clinical isolates of M. 
fortuitum seem to be highly conserved whilst there appears to be greater variation with other 
NTM-related mycobacteria. It should be noted that M. abscessus, like M. fortuitumisa rapidly 
growing mycobacteria (RGM) and forms part of the M. fortuitumcomplex. However, 
although M. abscessus shared the same clade as M. fortuitum, the formation of discrete 
























Figure 4.6 Dendrogram created from hierarchical cluster analysis of the main spectral profiles (MSP) of 
ATCC-typed strains and clinical isolates of mycobacteria using the CMEFA sample preparation protocol. 
4.5 DISCUSSION 
This is the first study that has generated a localMALDI-TOF main spectral profile (MSP) 
database for the explicit purpose of biotypingclinically significant mycobacterial 
isolatesusing CMEFA sample preparation protocol.The diagnosis of MTB as the causative 
agent of pulmonary TB using only clinical symptoms may be inadequate and inaccurate 
sinceM.bovis, M.avium, M.kansasii, and M.intracellulareall produce pulmonary disease in 
humans that may be indistinguishable from that caused by MTB[4,28].In this regard, the 
potential of the CMEFAsample preparation protocol was evaluated for a rapid and reliable 
discrimination of clinical relevant mycobacterial isolates using MALDI-TOF MS. 
 
The data from this present study clearly demonstrates that the newly developed organic 
solvent-based CMEFA protein extraction method which is cost-effective and simple to 
perform is highly efficient in producing mycobacterial cellular protein samples for MALDI-
TOF MS analysis to generate high resolution MSP’s. In addition, the independent CMEFA-
MSP-reference library containing MSP’s of ATCC-typed strains were used in the 
undisputable differentiation of blind-coded clinical mycobacterial isolates sourced from an 
independent research facility. All 39 blind-coded clinical mycobacterial isolates representing 
eight different mycobacteria were identified with 100% accuracyto the species level(log score 
values ≥ 2.3).Members of the MTBC family (M. tuberculosis and M. bovis) were 
unambiguously differentiated from each other and also from mycobacteria representing 
NTMclinical isolates.Although our study shares similar findings to that of Saleeb and co-
workers in terms of differentiation of clinical relevant mycobacterial isolates, it should be 
highlighted that the previous study madeidentifications with lower log score values ranging 
from 1.8 to ≥ 2 which are only reflective of probable species only as per Bruker Daltonic. In 
this respect it seems that the CMEFA-based MALDI-TOF MS mycobacterial biotyping 
strategy employed in this study is superior to EFAGB-based strategy used by Saleebet al. 
which did not clearly resolve or distinguish between MTBC-related mycobacteria [25]. 
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According to Gutackeret al., genomic differences can be seen at the protein level[29]. Thus it 
can be suggested that the unambiguous classification of the clinical mycobacterial isolates 
employed in this study were achievedthrough therecognition of differences in the 
proteomicprofilesof clinical isolates. It has also been reported that the proteomic profiling of 
intact mycobacteria using MALDI-TOF MS analysis is based on conserved ribosomal 
proteins thatare abundantly expressed within the cells[25,30,31]. In this study, cluster 
analysis based on a matrix of pair wise correlation values of all clinical mycobacterial 
MSP’sresulted in two separate clusters at the species level, one for MTBC members and the 
other including all clinical isolates of the NTM. Within the second cluster, NTM isolates 
formed discrete clusters with biologically similar isolates clustering closer together.Of 
significance, is thatthe closely related organismsM. abscessusand M. fortuitum (M. 
fortuitumcomplex) shared the same clade and formed discrete clustersresulting in 
phylogenetic discrimination of these two organisms.Similar findings were observed for M. 
avium and M.intracellulare isolates.In this respect it seems that the CMEFA-based MALDI-
TOF MS mycobacterial biotyping strategy employed in this study is superior to EFAGB-
based strategy used by Saleebet al. which did not clearly resolve or distinguishsimilar NTM-
related mycobacteria[25]. 
 
The use of the newly developed CMEFA protein extraction protocolseems to havefacilitated 
the removal of unwanted lipids and physiological salts, both of which are likely to interfere 
with matrix crystallization and spectral quality[32]thereby increasing the quality of the mass 
signals. Overall in comparison to the spectra obtained by Saleeb and co-researches, a 
significantly increased number of diagnostic ions in the mass/charge range of 2 to 10 kDa 
were observed for CMEFA-derived samples and are most probably reflective of higher 
protein content samples. 
 
This study joins the relatively few studies available describing a specific protein extraction 
protocol that is useful for all types of mycobacteria. Although the newly developed reference 
library was not as comprehensive as those described in previous studies [12,19,21,24,25], the 
potential of the library was observed for the unequivocal discrimination of clinically relevant 
mycobacterial isolates frequently associated with disease in our local setting. In addition to 
the above, a platform is now available for the addition of other species of mycobacteria into 
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the database as needs arise. This is an important milestone since the number of species within 
the genus Mycobacterium is ever expanding hence diagnostic laboratories need to 
continuously employ strategies to identify new emerging mycobacterial pathogens. Although 
the CMEFA-based MALDI-TOF MS mycobacterial biotyping strategy remains to be ratified 
in other independent laboratories, this study demonstrates its viable potential as a simple and 
cost effective diagnostic tool that providesrapid results (approximately 2 hours). Moreover 
the system lends itself to automation thereby permitting high throughput workflow. 
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5.1  GENERAL DISCUSSION AND CONCLUSION 
Mycobacterium tuberculosis remains the causative agent of tuberculosis (TB) disease 
worldwide with Southern Africa being the most affected sub-Saharan country. Tuberculosis 
disease is found to be the leading cause of death in people living with HIV and AIDS, and in 
a high HIV prevalence setting such as South Africa, TB is often the first sign of HIV 
infection[1,2]. In 2006, an outbreak of a deadly and almost incurable form of TB was 
reported in a rural community of KwaZulu-Natal province in South Africa[1]. The deadly 
strain of TB known as extensively drug-resistant TB (XDR-TB) occurred among HIV-
infected people[1] and was found to be resistant to both first and second-line anti-tuberculosis 
drugs. Fifty two of the 53 patients diagnosed with the disease at the time of the outbreak, died 
on average within 16 days of diagnosis[1].  
 
As much as the emergence of multi drug resistant (MDR) and extensive drug resistant (XDR) 
strains of MTB have contributed to the burden of tuberculosis disease, the apparent increase 
in the number of infections caused by the NTM have also been observed in the era of the 
HIV/AIDS epidemic, with a high level of interest of NTM disease occurring in AIDS 
patients[3-5]. Of concern is that in developed countries NTM play a significant role in the 
aetiology of tuberculosis-like syndromes, especially in HIV-positive patients[3,6,7].Of note 
the prevalence of pulmonary NTM in developing countries remains unknown and may be 
underestimated [22]due to a lack of routine culture and identification methods. Even though 
the prevalence of NTM can only be estimated, there is sufficient evidence to show that NTM 
infection rates and actual disease are increasing [3].  
 
Recently there has been a dramatic increase not only in the total number of NTM 
mycobacterial species but also in the number of clinically significant species [23].Prevalence 
rates of NTM colonization and infection have been reported in two epidemiological studies 
conducted in South Africa. The prevalence rates were found to be 1,400 and 6,700 per 
100,000, respectively when results of sputum cultures from South African native people were 
analysed [7-10]. Anotherstudy conducted on South African gold miners showed the annual 
rates of NTM infection to be 101 per 100 000 with M. kansasii(66/100,000) and M. 
scrofulaceum(12/100,000) being the two most common organisms isolated [3,5,11-13]. 
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Conventional laboratory methods for the identification of NTM and MTBC organisms rely on 
phenotypic characterization (growth rate, colony morphology, pigment production and 
staining techniques) and biochemical profiling. However, the main disadvantages associated 
with these methods are their extensive processing times (6-12 weeks to confirm a positive 
identification), which are considerably intensive in terms of both labour and cost [7]. A drive 
to unequivocally discriminate microbes of both MTBC and NTM families and to speed up 
their presumptive identification as witnessed the development of a number of molecular 
biology-based strategies which include the hybridisation of PCR generated amplicons to 
specific probes and 16SrRNA gene sequencing. These methods have found favour in well-
resourced privately- and government-owned pathology laboratories, as they are technically 
demanding and are dependent on expensive laboratory consumables and equipment. These 
methods are proving to be quiet effective for the detection of specific Mycobacterium species 
within 3 weeks thus contributing positively to both patient care and prognosis. Unfortunately, 
only a limited number of mycobacterial species can be identified by these molecular biology-
based assays [14]. 
 
Recent advances in the field of mass spectrometry have made it possible to use matrix–
assisted laser desorption/ ionization time-of- flight mass spectrometry (MALDI-TOF-MS) to 
aid in the identification of mycobacterial species by proteomic profiling[15,16].A wide 
variety of prokaryotes have been characterized using this approach, including clinically and 
environmentally relevant Gram positive and negative bacteria. However a limited number of 
studies have shown the potential of MALDI-TOF MSfor the proteomic profiling of various 
mycobacteria including M. tuberculosis[15-21]. To date there seems to be no consensus on 
which sample preparation method is preferred in the discrimination of mycobacteria. In this 
regard, the present study assessed the feasibility of using MALDI-TOF MS proteomic 
profiling as a rapid and precise technology to identify clinically-relevant mycobacteria in 
Kwazulu-Natal, South Africa. Eleven different mycobacterial species consisting of American 
Type Culture Collection (ATCC) strains representing four major groups: the MBTC, the 
MAC, the rapid, and the slow growing mycobacteria were employed in the proteomic 
profiling of mycobacteria by MALDI-TOF MS using a CMEFA sample preparation protocol. 
 
Our data clearly illustrated that the standard EFAsample preparation method although used 
for other genera of bacteria was inefficient for the isolation of proteins from ATCC-typed 
mycobacterial strains resulting in poor mass peak intensities for organism identification.It 
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was hypothesized that mechanical agitation with micro-glass beads employed in the EFAGB 
sample preparation method would break mycobacterial cell envelopes and release proteins 
needed for the accurate identification by MALDI-TOF MS [6]. However, ATCC typed 
mycobacterial strains processed by the EFAGB method yielded protein mass spectral profiles 
with low intensities and noise peaks,precluding organism identification. This was not 
unexpected since strain identification and discrimination which are likely due to differences 
in the relative abundance of shared mass to charge(m/z)values of ions from different 
organisms would be impossible when few peaks are obtained[19,22].  
 
Thus far, the data obtained in the present study has shown that when using the newly 
developed CMEFA sample preparation protocol coupled with HCCA (α-cyano-4-
hydroxycinnamic acid) as the MALDI matrix, highly reproducible and distinctive mass 
spectral fingerprints of ATCC typed mycobacterial strains were obtained. Thecreation of 
anindependent CMEFA-MSP reference library containing the MSP’s of ATCC-typed stains 
was used for the explicit purpose of biotyping clinically relevant mycobacterial isolates.All 
39 blind-coded clinical mycobacterial isolates representing eight different species were 
accurately identified (log scores >2.3) to both the genus and species levels. Cluster analysis 
based on a matrix of pair wise correlation values of all mycobacterial spectra produced two 
separate clusters at the species level, one for the MTBand the other including all isolates of 
the NTM. Within the second cluster, NTM isolates of the respective species formed discrete 
clusters with biologically similar isolates clustering closer together.  
 
Based on results obtained in this study, it can be seen that MALDI-TOF MS is an ideal 
biotyping tool for the identification of mycobacteria, as it allows for the testing of a large 
number of isolates, provides rapid results (approximately 2 hours), requires easy and 
relatively inexpensive procedures, and permits automation. This is thus the first study to 
establish the potential of MALDI-TOF MS as a rapid biotyping tool for the identification of 
clinically significant mycobacteria using a CMEFA sample extraction protocol. The initial 
acquisition cost of this facility is extremely expensive, however; routine maintenance and 
reagent consumables are economical. It is also noted that a far lower degree of technical 
expertise is required in the sample preparation and analysis for this technology. It can thus be 
of high value to both routine and reference laboratories given the highly variable infection 
manifestations of mycobacteria. 
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The performance of MALDI-TOF MS as a powerful biotyping tool for the identification of 
mycobacteria can only improve as more spectra of appropriate reference strains are added to 
the newly created independent database. A realistic expectation is that a well-established 
database that is clinically validated will contribute immensely to the diagnosis of tuberculosis 
and other mycobacteriosis. In future, this technology has potential to greatly assist in the 
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